Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,300 | 2022-06-29 00:00:00 UTC | Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-first-trust-health-care-alphadex-etf-fxh-2 | null | null | Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the First Trust Health Care AlphaDEX ETF (FXH), a passively managed exchange traded fund launched on 05/08/2007.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low co... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report It has amassed assets over $1.38 billion, making it one of the larger ETFs a... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care ... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care ... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report You should consider the First Trust Health Care AlphaDEX ETF (FXH), a passiv... |
23,301 | 2022-06-28 00:00:00 UTC | 2 Buffett Stocks That Outperformed the S&P During the Great Recession | ABBV | https://www.nasdaq.com/articles/2-buffett-stocks-that-outperformed-the-sp-during-the-great-recession | null | null | There are two things that Teva Pharmaceutical Industries (NYSE: TEVA) and Amazon (NASDAQ: AMZN) have in common. They've both been investments that Warren Buffett's Berkshire Hathaway held in its portfolio (Amazon is a current holding while Teva was recently sold) , and they both outperformed the S&P 500 during the Grea... | One example is AbbVie's rheumatoid arthritis medicine, Humira, which faces patent expiration next year. They've both been investments that Warren Buffett's Berkshire Hathaway held in its portfolio (Amazon is a current holding while Teva was recently sold) , and they both outperformed the S&P 500 during the Great Recess... | One example is AbbVie's rheumatoid arthritis medicine, Humira, which faces patent expiration next year. While Teva outperformed the markets 15 years ago, that hasn't been the case of late. The Motley Fool has positions in and recommends Amazon and Berkshire Hathaway (B shares). | One example is AbbVie's rheumatoid arthritis medicine, Humira, which faces patent expiration next year. They've both been investments that Warren Buffett's Berkshire Hathaway held in its portfolio (Amazon is a current holding while Teva was recently sold) , and they both outperformed the S&P 500 during the Great Recess... | One example is AbbVie's rheumatoid arthritis medicine, Humira, which faces patent expiration next year. While Teva outperformed the markets 15 years ago, that hasn't been the case of late. There's still some good value in the stock today, but investors shouldn't expect safety with the tech giant during a recession. |
23,302 | 2022-06-27 00:00:00 UTC | AbbVie: Europe's CHMP Recommends To Approve Upadacitinib To Treat Active Nr-axSpA Patients | ABBV | https://www.nasdaq.com/articles/abbvie%3A-europes-chmp-recommends-to-approve-upadacitinib-to-treat-active-nr-axspa-patients | null | null | (RTTNews) - AbbVie (ABBV) announced Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended the approval of upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis or nr-axSpA.
The European Union decision is expected i... | (RTTNews) - AbbVie (ABBV) announced Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended the approval of upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis or nr-axSpA. The CHMP positive opinion is based on res... | (RTTNews) - AbbVie (ABBV) announced Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended the approval of upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis or nr-axSpA. The CHMP positive opinion is a scientific... | (RTTNews) - AbbVie (ABBV) announced Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended the approval of upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis or nr-axSpA. The CHMP positive opinion is a scientific... | (RTTNews) - AbbVie (ABBV) announced Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended the approval of upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis or nr-axSpA. The European Union decision is expected i... |
23,303 | 2022-06-27 00:00:00 UTC | AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-rinvoq-gets-chmp-nod-for-new-indication | null | null | AbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor drug — Rinvoq (upadacitinib) — for yet another new indication.
The committee recommended approval of once-dai... | AbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor drug — Rinvoq (upadacitinib) — for yet another new indication. Shares of AbbVie have rallied 12.5% so far thi... | AbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor drug — Rinvoq (upadacitinib) — for yet another new indication. Shares of AbbVie have rallied 12.5% so far thi... | Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #4 (Sell). AbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor drug — Rinvoq (upadacitinib)... | AbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor drug — Rinvoq (upadacitinib) — for yet another new indication. Shares of AbbVie have rallied 12.5% so far thi... |
23,304 | 2022-06-27 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2 | null | null | AbbVie (ABBV) closed at $153.14 in the latest trading session, marking a +0.53% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.3%. Elsewhere, the Dow lost 0.2%, while the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the drugmaker had gained 1.56% in the past month. In that same t... | AbbVie (ABBV) closed at $153.14 in the latest trading session, marking a +0.53% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $153.14 in the latest trading session, marking a +0.53% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $153.14 in the latest trading session, marking a +0.53% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $153.14 in the latest trading session, marking a +0.53% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbVie. |
23,305 | 2022-06-27 00:00:00 UTC | Is AbbVie About To Get A New Blockbuster Drug? | ABBV | https://www.nasdaq.com/articles/is-abbvie-about-to-get-a-new-blockbuster-drug | null | null | Last month, AbbVie (NYSE: ABBV) submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the compound ABBV-951 to treat motor fluctuations in patients with advanced Parkinson's disease.
The pharma company expects to make more submissions to other regulatory authorities in the months ahead for... | Patients with advanced Parkinson's disease were randomized into two groups for AbbVie's phase 3 clinical trial that evaluated the efficacy of the drug in controlling motor fluctuations. Though specific data from the phase 3 clinical trials hasn't yet been released, AbbVie noted that the group receiving ABBV-951 and ora... | Patients with advanced Parkinson's disease were randomized into two groups for AbbVie's phase 3 clinical trial that evaluated the efficacy of the drug in controlling motor fluctuations. Though specific data from the phase 3 clinical trials hasn't yet been released, AbbVie noted that the group receiving ABBV-951 and ora... | Last month, AbbVie (NYSE: ABBV) submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the compound ABBV-951 to treat motor fluctuations in patients with advanced Parkinson's disease. AbbVie says an estimated 50% of Parkinson's disease patients progress to advanced disease within two years ... | AbbVie says an estimated 50% of Parkinson's disease patients progress to advanced disease within two years of diagnosis, and 80% to 100% of patients reach that stage after 10 years. The company anticipates that ABBV-951 will achieve $1 billion in peak annual sales potential, making it a blockbuster drug. Last month, Ab... |
23,306 | 2022-06-27 00:00:00 UTC | 5 Best Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/5-best-dividend-stocks-to-buy-now | null | null | In this video, I will be talking about five dividend-paying companies that you might want to add to your portfolio. Dividend stocks can provide stability during rough times like today. Intel (NASDAQ: INTC) is currently the only one in my portfolio, but I might add more in these coming months.
For the full insights, do ... | For the full insights, do watch the video, consider subscribing, and click the special offer link below. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. If you choose to subscribe through his link, he will earn some extra money that supports his channel. | After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Neil Rozenbaum has positions in Intel. The Motley Fool recommends the following options: long January 2023 $57.50 calls on Intel, long January 2024 $4... | 10 stocks we like better than Intel When our award-winning analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Neil Rozenbaum has positions in Intel. The Motley Fool recommends the following options: long January 2023 $57.50 calls on Intel, long January 2024 $... | The video was published on June 26, 2022. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Neil Rozenbaum has positions in Intel. The Motley Fool has positions in and recommends Intel, Qualcomm, and Starbucks. |
23,307 | 2022-06-26 00:00:00 UTC | 4 Top Dividend Stocks To Watch Amid Recession Concerns | ABBV | https://www.nasdaq.com/articles/4-top-dividend-stocks-to-watch-amid-recession-concerns | null | null | Check Out These Dividend Stocks For Your Late June Watchlist
As the stock market appears to be attempting a recovery, there remains plenty of uncertainty. Thus, dividend stocks could be on the minds of investors. For one, companies that can pay dividends to their shareholders are often those with a track record of prof... | A prime example of a dividend stock would be AbbVie (NYSE: ABBV). Since the company’s establishment in 2013, AbbVie has raised its dividend by more than 250%. As it stands, ABBV stock now yields a 3.8% annual dividend yield. | A prime example of a dividend stock would be AbbVie (NYSE: ABBV). Since the company’s establishment in 2013, AbbVie has raised its dividend by more than 250%. As it stands, ABBV stock now yields a 3.8% annual dividend yield. | A prime example of a dividend stock would be AbbVie (NYSE: ABBV). Since the company’s establishment in 2013, AbbVie has raised its dividend by more than 250%. As it stands, ABBV stock now yields a 3.8% annual dividend yield. | A prime example of a dividend stock would be AbbVie (NYSE: ABBV). Since the company’s establishment in 2013, AbbVie has raised its dividend by more than 250%. As it stands, ABBV stock now yields a 3.8% annual dividend yield. |
23,308 | 2022-06-26 00:00:00 UTC | 3 Top Dividend Stocks for Generating Passive Income | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-for-generating-passive-income | null | null | You can work for money. But you can also have your money work for you. One great way to make passive income is to invest in dividend stocks.
We asked three Motley Fool contributors to identify top dividend stocks for generating passive income. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD)... | AbbVie's acquisition of Allergan in 2020 also added several growth drivers to its lineup, notably including the Botox franchise and antipsychotic drug Vraylar. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Let this Dividend King serve you Keith Speights (AbbVie): O... | Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Let this Dividend King serve you Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings. AbbVie ranks as a member of this exclusive club with 50 consecutive years of dividend increases. | Let this Dividend King serve you Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). AbbVie ranks as a member of this exclusive club with 50 consecutive years of dividend increases. | Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Let this Dividend King serve you Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings. AbbVie ranks as a member of this exclusive club with 50 consecutive years of dividend increases. |
23,309 | 2022-06-24 00:00:00 UTC | Daily Dividend Report: ABBV,EIX,DTE,BFS,BKSC | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-abbveixdtebfsbksc | null | null | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable August 15, 2022, to stockholders of record at the close of business on July 15, 2022. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a ... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... |
23,310 | 2022-06-23 00:00:00 UTC | Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip | ABBV | https://www.nasdaq.com/articles/got-%241000-buy-these-2-ultra-high-yield-dividend-stocks-on-the-dip | null | null | Sometimes a stock falls to levels so low, it almost doesn't matter what an investor's budget is -- they have to buy at least a few shares to take advantage of the situation. With the market's retreat lately, a great many stocks are at, or teasing, their recent low-water marks.
This presents some nearly irresistible opp... | As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks. AbbVie Another Dividend King with a tarnished crown is pharmaceutical ... | As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks. AbbVie Another Dividend King with a tarnished crown is pharmaceutical ... | As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks. AbbVie Another Dividend King with a tarnished crown is pharmaceutical ... | AbbVie Another Dividend King with a tarnished crown is pharmaceutical sector giant AbbVie. As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S... |
23,311 | 2022-06-22 00:00:00 UTC | Noteworthy Wednesday Option Activity: SPLK, C, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-splk-c-abbv | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Splunk Inc (Symbol: SPLK), where a total volume of 10,501 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that e... | Particularly high volume was seen for the $160 strike call option expiring August 19, 2022, with 1,454 contracts trading so far today, representing approximately 145,400 underlying shares of ABBV. Particularly high volume was seen for the $47 strike put option expiring July 15, 2022, with 8,406 contracts trading so far... | Particularly high volume was seen for the $47 strike put option expiring July 15, 2022, with 8,406 contracts trading so far today, representing approximately 840,600 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $47 strike highlighted in orange: And AbbVie Inc (Sym... | Particularly high volume was seen for the $47 strike put option expiring July 15, 2022, with 8,406 contracts trading so far today, representing approximately 840,600 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $47 strike highlighted in orange: And AbbVie Inc (Sym... | Particularly high volume was seen for the $47 strike put option expiring July 15, 2022, with 8,406 contracts trading so far today, representing approximately 840,600 underlying shares of C. Below is a chart showing C's trailing twelve month trading history, with the $47 strike highlighted in orange: And AbbVie Inc (Sym... |
23,312 | 2022-06-22 00:00:00 UTC | What Stocks To Invest In Today? 3 Pharmaceutical Stocks To Watch | ABBV | https://www.nasdaq.com/articles/what-stocks-to-invest-in-today-3-pharmaceutical-stocks-to-watch | null | null | 3 Pharmaceutical Stocks For Your Watchlist Right Now
For investors wondering what are the best stocks to invest in today, pharmaceutical stocks would be an interesting play. On the whole, this part of the stock market is home to companies of varying sizes and specializations. The likes of which serve to aid people acro... | “Having one oral medication to treat both episodic and chronic migraine would be an important advancement for health care providers and patients,” said Michael Gold, M.D., therapeutic area head, neuroscience development, AbbVie. Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) ANI Pharmaceuticals Inc. (NAS... | Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Merck & Co. Inc. (NYSE: MRK) AbbVie Inc. AbbVie is a biopharmaceutical company that was a spin-off from Abbott Laboratories (NYSE: ABT). “This sNDA approval would also diversify AbbVie’s migraine portfolio and make it ... | Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Merck & Co. Inc. (NYSE: MRK) AbbVie Inc. AbbVie is a biopharmaceutical company that was a spin-off from Abbott Laboratories (NYSE: ABT). “Having one oral medication to treat both episodic and chronic migraine would be ... | Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Merck & Co. Inc. (NYSE: MRK) AbbVie Inc. AbbVie is a biopharmaceutical company that was a spin-off from Abbott Laboratories (NYSE: ABT). “Having one oral medication to treat both episodic and chronic migraine would be ... |
23,313 | 2022-06-22 00:00:00 UTC | HDV, ABBV, PM, BMY: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/hdv-abbv-pm-bmy%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $184.8 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 124,600,00... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Philip Morris International Inc (Symbol: PM) is off about 1.8%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.6%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Philip Morris International Inc (Symbol: PM) is off about 1.8%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.6%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Philip Morris International Inc (Symbol: PM) is off about 1.8%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Philip Morris International Inc (Symbol: PM) is off about 1.8%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs... |
23,314 | 2022-06-22 00:00:00 UTC | AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-files-qulipta-snda-for-chronic-migraine-prevention | null | null | AbbVie ABBV submitted a supplemental new drug application (sNDA) with the FDA, seeking approval for the expanded use of its newly approved CGRP receptor antagonist, Qulipta (atogepant), for the prevention of chronic migraine.
Qulipta was approved for the preventive treatment of episodic migraine in adults in September ... | AbbVie ABBV submitted a supplemental new drug application (sNDA) with the FDA, seeking approval for the expanded use of its newly approved CGRP receptor antagonist, Qulipta (atogepant), for the prevention of chronic migraine. AbbVie’s stock has risen 5.9% this year so far against a decrease of 2.6% for the industry. Ab... | AbbVie ABBV submitted a supplemental new drug application (sNDA) with the FDA, seeking approval for the expanded use of its newly approved CGRP receptor antagonist, Qulipta (atogepant), for the prevention of chronic migraine. AbbVie’s stock has risen 5.9% this year so far against a decrease of 2.6% for the industry. Ab... | AbbVie ABBV submitted a supplemental new drug application (sNDA) with the FDA, seeking approval for the expanded use of its newly approved CGRP receptor antagonist, Qulipta (atogepant), for the prevention of chronic migraine. AbbVie’s stock has risen 5.9% this year so far against a decrease of 2.6% for the industry. Ab... | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie ABBV submitted a supplemental new drug application (sNDA) with the FDA, seeking approval for the expanded use of its newly approved CGRP receptor antagonist, Qulipta (atogepant), for the prevention of chronic migraine. AbbVie’s stock has risen 5.9% this year so far ... |
23,315 | 2022-06-22 00:00:00 UTC | Better Buy: Dividend Stocks or Growth Stocks? | ABBV | https://www.nasdaq.com/articles/better-buy%3A-dividend-stocks-or-growth-stocks | null | null | With the market moving to a risk-off environment, the question of whether to buy dividend stocks or growth stocks is top of mind for investors.
The answer lies in understanding your own personal investor profile. While some may argue dividend-paying stocks are a safer place to put your money as multiples condense, many... | Some examples of strong dividend-paying businesses include: Coca Cola (NYSE: KO) -- pays a dividend of 2.96% AbbVie (NYSE: ABBV) -- pays a dividend of 4.08% In addition to the dividends, both of these stocks are slightly up in 2022, in a year where the S&P 500 is down over 20%. Finally, mature businesses will often ele... | Some examples of strong dividend-paying businesses include: Coca Cola (NYSE: KO) -- pays a dividend of 2.96% AbbVie (NYSE: ABBV) -- pays a dividend of 4.08% In addition to the dividends, both of these stocks are slightly up in 2022, in a year where the S&P 500 is down over 20%. The importance of understanding business ... | Some examples of strong dividend-paying businesses include: Coca Cola (NYSE: KO) -- pays a dividend of 2.96% AbbVie (NYSE: ABBV) -- pays a dividend of 4.08% In addition to the dividends, both of these stocks are slightly up in 2022, in a year where the S&P 500 is down over 20%. With the market moving to a risk-off envi... | Some examples of strong dividend-paying businesses include: Coca Cola (NYSE: KO) -- pays a dividend of 2.96% AbbVie (NYSE: ABBV) -- pays a dividend of 4.08% In addition to the dividends, both of these stocks are slightly up in 2022, in a year where the S&P 500 is down over 20%. With the market moving to a risk-off envi... |
23,316 | 2022-06-22 00:00:00 UTC | AbbVie: Health Canada Approves Label Extension For MAVIRET To Include Use In Paediatric Patients | ABBV | https://www.nasdaq.com/articles/abbvie%3A-health-canada-approves-label-extension-for-maviret-to-include-use-in-paediatric | null | null | (RTTNews) - AbbVie (ABBV) announced Health Canada has approved a change in the marketing authorization for MAVIRET to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg. It is now approved as an 8-week, pan-genotypic treatment for treatment-naïve, chroni... | (RTTNews) - AbbVie (ABBV) announced Health Canada has approved a change in the marketing authorization for MAVIRET to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg. It is now approved as an 8-week, pan-genotypic treatment for treatment-naïve, chroni... | (RTTNews) - AbbVie (ABBV) announced Health Canada has approved a change in the marketing authorization for MAVIRET to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg. It is now approved as an 8-week, pan-genotypic treatment for treatment-naïve, chroni... | (RTTNews) - AbbVie (ABBV) announced Health Canada has approved a change in the marketing authorization for MAVIRET to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg. It is now approved as an 8-week, pan-genotypic treatment for treatment-naïve, chroni... | (RTTNews) - AbbVie (ABBV) announced Health Canada has approved a change in the marketing authorization for MAVIRET to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg. It is now approved as an 8-week, pan-genotypic treatment for treatment-naïve, chroni... |
23,317 | 2022-06-21 00:00:00 UTC | AbbVie Files SNDA For Atogepant For Label Expansion | ABBV | https://www.nasdaq.com/articles/abbvie-files-snda-for-atogepant-for-label-expansion | null | null | (RTTNews) - AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. The company noted that the submission is based on pivotal phase 3 PROGRESS chronic migraine study evaluating atogepant in adult patients th... | (RTTNews) - AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. Michael Gold, therapeutic area head, neuroscience development, AbbVie, said: "This sNDA approval would also diversify AbbVie's migraine por... | (RTTNews) - AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. Michael Gold, therapeutic area head, neuroscience development, AbbVie, said: "This sNDA approval would also diversify AbbVie's migraine por... | (RTTNews) - AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. Michael Gold, therapeutic area head, neuroscience development, AbbVie, said: "This sNDA approval would also diversify AbbVie's migraine por... | (RTTNews) - AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. Michael Gold, therapeutic area head, neuroscience development, AbbVie, said: "This sNDA approval would also diversify AbbVie's migraine por... |
23,318 | 2022-06-20 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-3 | null | null | AbbVie (ABBV) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. This change lagged the S&P 500's daily gain of 0.22%. Elsewhere, the Dow lost 0.13%, while the tech-heavy Nasdaq added 0.22%.
Coming into today, shares of the drugmaker had lost 8.43% in the past month. In that... | AbbVie (ABBV) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | AbbVie (ABBV) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | AbbVie (ABBV) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | AbbVie (ABBV) closed the most recent trading day at $138.28, moving -0.63% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.43 per share. |
23,319 | 2022-06-20 00:00:00 UTC | AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-skyrizi-gets-fda-nod-for-crohns-disease | null | null | AbbVie ABBV announced that the FDA has approved its drug Skyrizi (risankizumab) for its third indication, moderately to severely active Crohn’s disease (“CD”).
Skyrizi can now be used as a 600mg intravenous induction at week 0, week 4, and week 8, followed by 360 mg self-administered by subcutaneous injection with an ... | AbbVie ABBV announced that the FDA has approved its drug Skyrizi (risankizumab) for its third indication, moderately to severely active Crohn’s disease (“CD”). AbbVie’s stock has risen 2.1% this year so far against a decrease of 2.6% for the industry. Image Source: Zacks Investment Research In September last year, the ... | AbbVie ABBV announced that the FDA has approved its drug Skyrizi (risankizumab) for its third indication, moderately to severely active Crohn’s disease (“CD”). AbbVie’s stock has risen 2.1% this year so far against a decrease of 2.6% for the industry. Image Source: Zacks Investment Research In September last year, the ... | Zacks Rank and Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). AbbVie ABBV announced that the FDA has approved its drug Skyrizi (risankizumab) for its third indication, moderately to severely active Crohn’s disease (“CD”). AbbVie’s stock has risen 2.1% this year so far against a decrease of 2.6% for the... | AbbVie ABBV announced that the FDA has approved its drug Skyrizi (risankizumab) for its third indication, moderately to severely active Crohn’s disease (“CD”). AbbVie’s stock has risen 2.1% this year so far against a decrease of 2.6% for the industry. Image Source: Zacks Investment Research In September last year, the ... |
23,320 | 2022-06-20 00:00:00 UTC | Finally, a Reasonable Price For This Healthcare Blue Chip | ABBV | https://www.nasdaq.com/articles/finally-a-reasonable-price-for-this-healthcare-blue-chip | null | null | The investor community holds high regard for healthcare conglomerate Abbott Laboratories (NYSE: ABT). Shares rarely come cheap, typically commanding a higher valuation than the S&P 500.
However today Abbott Labs is trading nearly 30% below its high, thanks to recent volatility on Wall Street.
The stock has crushed the ... | You can see below how steadily Abbott has grown over these decades, except for a massive spin-off in 2013 to form AbbVie from its pharmaceutical segment. A profitable business giving cash to investors Healthcare has changed so much over time, so Abbott's dividend track record might best speak for its long-term success.... | You can see below how steadily Abbott has grown over these decades, except for a massive spin-off in 2013 to form AbbVie from its pharmaceutical segment. COVID-19 carrying growth in the near term Abbott Labs is a healthcare company that designs and sells various products, including consumer products, generic drugs, med... | You can see below how steadily Abbott has grown over these decades, except for a massive spin-off in 2013 to form AbbVie from its pharmaceutical segment. Abbott's total revenue grew by 13.8% year over year in Q1; COVID-19 rapid test sales could eventually fade, but Abbott's a diverse company that grows in many ways. Ab... | You can see below how steadily Abbott has grown over these decades, except for a massive spin-off in 2013 to form AbbVie from its pharmaceutical segment. COVID-19 carrying growth in the near term Abbott Labs is a healthcare company that designs and sells various products, including consumer products, generic drugs, med... |
23,321 | 2022-06-19 00:00:00 UTC | Want to Retire Early? These 5 Ultra-High-Yield Dividend Stocks Can Help | ABBV | https://www.nasdaq.com/articles/want-to-retire-early-these-5-ultra-high-yield-dividend-stocks-can-help | null | null | Retirement doesn't necessarily have to wait until you are in your 60s; working becomes optional as soon as your passive income covers your living expenses.
Buying dividend stocks, which make so much money that they give a chunk of their profits on a regular basis to shareholders, can eventually build a waterfall of cas... | AbbVie: Pharmaceutical leader Dividend yield: 4% AbbVie (NYSE: ABBV) is a pharmaceutical company that was born when it split from Abbott Laboratories in 2013. ABBV Revenue (TTM) data by YCharts. AbbVie's exclusive rights to Humira in the U.S. expire next year, which will likely cause revenue growth to slow as competito... | AbbVie: Pharmaceutical leader Dividend yield: 4% AbbVie (NYSE: ABBV) is a pharmaceutical company that was born when it split from Abbott Laboratories in 2013. ABBV Revenue (TTM) data by YCharts. AbbVie's exclusive rights to Humira in the U.S. expire next year, which will likely cause revenue growth to slow as competito... | AbbVie: Pharmaceutical leader Dividend yield: 4% AbbVie (NYSE: ABBV) is a pharmaceutical company that was born when it split from Abbott Laboratories in 2013. ABBV Revenue (TTM) data by YCharts. AbbVie's exclusive rights to Humira in the U.S. expire next year, which will likely cause revenue growth to slow as competito... | AbbVie: Pharmaceutical leader Dividend yield: 4% AbbVie (NYSE: ABBV) is a pharmaceutical company that was born when it split from Abbott Laboratories in 2013. ABBV Revenue (TTM) data by YCharts. AbbVie's exclusive rights to Humira in the U.S. expire next year, which will likely cause revenue growth to slow as competito... |
23,322 | 2022-06-18 00:00:00 UTC | 3 Dividend Stocks to Double Up on Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-double-up-on-right-now | null | null | With the market tumbling and dividend yields rising, now is a great time to be loading up on great, cash-yielding stocks. If you can find the right businesses to invest in today, you stand to gain a considerable amount on your purchase in the long run, when the current turbulence is just a distant memory.
In this vein,... | AbbVie As a spinoff of Abbott Labs, AbbVie (NYSE: ABBV) is dedicated to developing and commercializing new prescription medicines. And it isn't as though AbbVie is struggling despite falling income from Humira; its quarterly revenue is up by more than 49% over the last three years, and its quarterly free cash flow (FCF... | AbbVie As a spinoff of Abbott Labs, AbbVie (NYSE: ABBV) is dedicated to developing and commercializing new prescription medicines. And it isn't as though AbbVie is struggling despite falling income from Humira; its quarterly revenue is up by more than 49% over the last three years, and its quarterly free cash flow (FCF... | AbbVie As a spinoff of Abbott Labs, AbbVie (NYSE: ABBV) is dedicated to developing and commercializing new prescription medicines. And it isn't as though AbbVie is struggling despite falling income from Humira; its quarterly revenue is up by more than 49% over the last three years, and its quarterly free cash flow (FCF... | AbbVie As a spinoff of Abbott Labs, AbbVie (NYSE: ABBV) is dedicated to developing and commercializing new prescription medicines. And it isn't as though AbbVie is struggling despite falling income from Humira; its quarterly revenue is up by more than 49% over the last three years, and its quarterly free cash flow (FCF... |
23,323 | 2022-06-17 00:00:00 UTC | First Week of February 2023 Options Trading For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/first-week-of-february-2023-options-trading-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the February 2023 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly trading contracts represent a potential opportunity for selle... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $140.00 strike highlighted in red: Considering the fact that the $140.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $135.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $140.00 strike price has a current bid of $10.20. Below is a chart showing AB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new February 2023 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $140.00 strike highlighted in red: Consi... |
23,324 | 2022-06-17 00:00:00 UTC | 5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began | ABBV | https://www.nasdaq.com/articles/5-stocks-warren-buffett-has-aggressively-sold-since-2022-began | null | null | When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention. That's because the Oracle of Omaha has delivered an aggregate return on the company's Class A shares (BRK.A) of 3,641,613% during his 57 years at the helm (through Dec. 31, 2021).
While r... | AbbVie: Sold all shares Bristol Myers isn't the only big drugmaker dumped by Warren Buffett's company this year. AbbVie (NYSE: ABBV), which was initially purchased by Berkshire Hathaway in 2020, was completely sold. The basis for selling all shares of AbbVie likely mirrored the reasoning for ditching Bristol Myers Squi... | AbbVie: Sold all shares Bristol Myers isn't the only big drugmaker dumped by Warren Buffett's company this year. AbbVie (NYSE: ABBV), which was initially purchased by Berkshire Hathaway in 2020, was completely sold. The basis for selling all shares of AbbVie likely mirrored the reasoning for ditching Bristol Myers Squi... | AbbVie: Sold all shares Bristol Myers isn't the only big drugmaker dumped by Warren Buffett's company this year. AbbVie (NYSE: ABBV), which was initially purchased by Berkshire Hathaway in 2020, was completely sold. The basis for selling all shares of AbbVie likely mirrored the reasoning for ditching Bristol Myers Squi... | AbbVie: Sold all shares Bristol Myers isn't the only big drugmaker dumped by Warren Buffett's company this year. AbbVie (NYSE: ABBV), which was initially purchased by Berkshire Hathaway in 2020, was completely sold. The basis for selling all shares of AbbVie likely mirrored the reasoning for ditching Bristol Myers Squi... |
23,325 | 2022-06-16 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned -9.4% over the past month versus the Zacks S&P 500 composite's -5.6% change. The Zacks Large C... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie... | Last Reported Results and Surprise History AbbVie reported revenues of $13.54 billion in the last reported quarter, representing a year-over-year change of +4.1%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lo... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs,... | For the next fiscal year, the consensus earnings estimate of $11.86 indicates a change of -15.4% from what AbbVie is expected to report a year ago. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 3.7% over th... |
23,326 | 2022-06-15 00:00:00 UTC | Is There A Better Pick Over Merck Stock In Animal Health Space? | ABBV | https://www.nasdaq.com/articles/is-there-a-better-pick-over-merck-stock-in-animal-health-space | null | null | We think that Zoetis stock (NYSE: ZTS) currently is a better pick compared to its peer Merck stock (NYSE: MRK), despite Zoetis being the more expensive of the two, trading at 9x trailing revenues, compared to just 4x for Merck. This valuation gap can be attributed to Zoetis’ better profitability.
If we look at stock re... | We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of Merck vs. Zoetis: Which Stock Is A Better Bet? Merck, over the recent quarters, has benefited from label expansion of Keytruda and a rebound in demand for vaccines, primarily Gardasil,... | It points to a CAGR of 1.6% for Merck, compared to a 7.2% CAGR for Zoetis, based on Trefis Machine Learning analysis. The table below summarizes our revenue and return expectations for Merck and Zoetis over the next three years and points to an expected return of 19% for Zoetis over this period vs. a 10% expected retur... | We think that Zoetis stock (NYSE: ZTS) currently is a better pick compared to its peer Merck stock (NYSE: MRK), despite Zoetis being the more expensive of the two, trading at 9x trailing revenues, compared to just 4x for Merck. If we look at stock returns, Merck’s 16% growth is much better than the -14% return for Zoet... | While both the companies are likely to see stock price growth, Zoetis is expected to outperform. Our Merck Revenue and Zoetis Revenue dashboards provide more insight into the companies’ sales. The table below summarizes our revenue and return expectations for Merck and Zoetis over the next three years and points to an ... |
23,327 | 2022-06-14 00:00:00 UTC | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-dips-more-than-broader-markets%3A-what-you-should-know | null | null | AbbVie (ABBV) closed the most recent trading day at $137.62, moving -1.29% from the previous trading session. This move lagged the S&P 500's daily loss of 0.38%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.46%.
Coming into today, shares of the drugmaker had lost 10.32% in the past month. In th... | AbbVie (ABBV) closed the most recent trading day at $137.62, moving -1.29% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | AbbVie (ABBV) closed the most recent trading day at $137.62, moving -1.29% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | AbbVie (ABBV) closed the most recent trading day at $137.62, moving -1.29% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | AbbVie (ABBV) closed the most recent trading day at $137.62, moving -1.29% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.43 per share. |
23,328 | 2022-06-14 00:00:00 UTC | Notable ETF Inflow Detected - HDV, ABBV, PM, BMY | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-hdv-abbv-pm-bmy | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $349.3 million dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 121,150,00... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Philip Morris International Inc (Symbol: PM) is up about 0.6%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 1.1%. For a complete list of holdings, visit the HDV Holdings page » The chart below ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Philip Morris International Inc (Symbol: PM) is up about 0.6%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 1.1%. For a complete list of holdings, visit the HDV Holdings page » The chart below ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Philip Morris International Inc (Symbol: PM) is up about 0.6%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe o... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Philip Morris International Inc (Symbol: PM) is up about 0.6%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe o... |
23,329 | 2022-06-14 00:00:00 UTC | Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata | ABBV | https://www.nasdaq.com/articles/lilly-lly-incytes-olumiant-gets-fda-nod-for-alopecia-areata | null | null | Eli Lilly LLY and partner Incyte INCY announced that the FDA has granted approval to their oral JAK inhibitor, Olumiant (baricitinib) for treating adults with severe alopecia areata (“AA”). This autoimmune disorder results in non-scarring hair loss.
Until now there were no FDA-approved systemic treatments for AA. Syste... | AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology medicine Humira are launched in the United States next year. Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie’s Rinvoq is approved for RA, psoriati... | AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... | Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... | Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... |
23,330 | 2022-06-14 00:00:00 UTC | The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-berkshire-hathaway-abbvie-totalenergies-linde-and-att | null | null | For Immediate Release
Chicago, IL – June 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.... | (You an read the full research report on Berkshire Hathaway here >>>) AbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+27.6% vs. +15.8%). Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. ABBV, TotalEnergies SE TTE, Linde plc LIN ... | Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. ABBV, TotalEnergies SE TTE, Linde plc LIN and AT&T Inc. T. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Berkshire Hathaway, AbVie and TotalEnergies The Zacks Research Daily presents the best research ou... | Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. ABBV, TotalEnergies SE TTE, Linde plc LIN and AT&T Inc. T. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Berkshire Hathaway, AbVie and TotalEnergies The Zacks Research Daily presents the best research ou... | (You an read the full research report on AbbVie here >>>) TotalEnergies shares have gained +44.3% over the past year against the Zacks Oil and Gas - Refining and Marketing industry's gain of +19.0%. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. ABBV, TotalEnergies SE TTE, Li... |
23,331 | 2022-06-13 00:00:00 UTC | Consistent Clinical Results Indicate Upside for AbbVie Stock | ABBV | https://www.nasdaq.com/articles/consistent-clinical-results-indicate-upside-for-abbvie-stock | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Illinois-headquartered AbbVie (NYSE:ABBV) is famous among pharmaceutical businesses for its diversified portfolio of medical treatments and solutions. ABBV stock is an outstanding deal at the current share price as AbbVie continues to develop industry-leadi... | ABBV stock is an outstanding deal at the current share price as AbbVie continues to develop industry-leading formulations through clinical trials. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illinois-headquartered AbbVie (NYSE:ABBV) is famous among pharmaceutical businesses for its diversified portfo... | Ticker Company Price ABBV AbbVie Inc. $141.34 What’s Happening with ABBV Stock? InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illinois-headquartered AbbVie (NYSE:ABBV) is famous among pharmaceutical businesses for its diversified portfolio of medical treatments and solutions. ABBV stock is an outstandi... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illinois-headquartered AbbVie (NYSE:ABBV) is famous among pharmaceutical businesses for its diversified portfolio of medical treatments and solutions. ABBV stock is an outstanding deal at the current share price as AbbVie continues to develop industry-leadi... | After delving into the company’s financials, investors should concur that AbbVie is a relatively low-risk pharmaceutical business to hold a stake in. Ticker Company Price ABBV AbbVie Inc. $141.34 What’s Happening with ABBV Stock? What You Can Do With ABBV Stock All in all, there’s no reason why ABBV stock shouldn’t rev... |
23,332 | 2022-06-13 00:00:00 UTC | Should You Invest in the VanEck Pharmaceutical ETF (PPH)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph-1 | null | null | If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investo... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 5.93% of total assets, followed by Bristol-Myers Squibb Co (BMY) and Mckesson Corp (MCK). AbbVie Inc. (ABBV): Free Stock Analysis Report If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further th... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 5.93% of total assets, followed by Bristol-Myers Squibb Co (BMY) and Mckesson Corp (MCK). AbbVie Inc. (ABBV): Free Stock Analysis Report Invesco Dynamic Pharmaceuticals ETF (PJP) tracks Dynamic Pharmaceutical Intellidex Index and the iShares U.S. Phar... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 5.93% of total assets, followed by Bristol-Myers Squibb Co (BMY) and Mckesson Corp (MCK). AbbVie Inc. (ABBV): Free Stock Analysis Report Invesco Dynamic Pharmaceuticals ETF (PJP) tracks Dynamic Pharmaceutical Intellidex Index and the iShares U.S. Phar... | AbbVie Inc. (ABBV): Free Stock Analysis Report Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 5.93% of total assets, followed by Bristol-Myers Squibb Co (BMY) and Mckesson Corp (MCK). If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further th... |
23,333 | 2022-06-13 00:00:00 UTC | Top Analyst Reports for Berkshire Hathaway, AbbVie & TotalEnergies | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-berkshire-hathaway-abbvie-totalenergies | null | null | Monday, June 13, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. (ABBV), and TotalEnergies SE (TTE). These research reports have been hand-picked from the ... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Berkshire (BRK.B) Continues to Gain From Insurance Business AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth Expanding LNG & Clean Energy Assets Aid TotalEnergies (TTE) Featured Reports Linde's... | Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. (ABBV), and TotalEnergies SE (TTE). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Berkshire (BRK.B) Continues to Gain From ... | (You an read the full research report on AbbVie here >>>) TotalEnergies shares have gained +44.3% over the past year against the Zacks Oil and Gas - Refining and Marketing industry’s gain of +19.0%. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Berksh... | (You an read the full research report on AbbVie here >>>) TotalEnergies shares have gained +44.3% over the past year against the Zacks Oil and Gas - Refining and Marketing industry’s gain of +19.0%. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), AbbVi... |
23,334 | 2022-06-13 00:00:00 UTC | AbbVie Enters Oversold Territory | ABBV | https://www.nasdaq.com/articles/abbvie-enters-oversold-territory | null | null | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... | A bullish investor could look at ABBV's 29.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which sugges... | In the case of AbbVie Inc, the RSI reading has hit 29.3 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 37.4. Indeed, ABBV's recent annualized dividend of 5.64/share (currently paid in quarterly installments) works out to an annual yield of 3.94% based upon t... | In the case of AbbVie Inc, the RSI reading has hit 29.3 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 37.4. AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interest... | Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further researc... |
23,335 | 2022-06-12 00:00:00 UTC | Top Biotech Stocks To Invest In Today? 3 To Watch This Week | ABBV | https://www.nasdaq.com/articles/top-biotech-stocks-to-invest-in-today-3-to-watch-this-week | null | null | Are These The Best Biotech Stocks To Buy Right Now?
Even with inflation data coming in hotter-than-expected, investors would likely be looking for the most active stocks today. Should this be the case, biotech stocks would make for a viable option in the stock market now. For the most part, this would be the case as th... | “The new data observed from SELECT-AXIS 2 reinforce the potential of upadacitinib for patients across the spectrum of axial spondyloarthritis disease,” said Neil Gallagher, M.D., Ph.D., vice president, development, chief medical officer, AbbVie. Biotech Stocks To Buy [Or Sell] This Month Pfizer Inc. (NYSE: PFE) AbbVie ... | Biotech Stocks To Buy [Or Sell] This Month Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Pfizer Inc. Pfizer is a biotech company that continues to bring life-saving therapies, medicines, and vaccines to the masses. 4 Metaverse Stocks To Watch AbbVie Inc. Following that, we have AbbVie, a ... | Biotech Stocks To Buy [Or Sell] This Month Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Pfizer Inc. Pfizer is a biotech company that continues to bring life-saving therapies, medicines, and vaccines to the masses. 4 Metaverse Stocks To Watch AbbVie Inc. Following that, we have AbbVie, a ... | Biotech Stocks To Buy [Or Sell] This Month Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Novavax Inc. (NASDAQ: NVAX) Pfizer Inc. Pfizer is a biotech company that continues to bring life-saving therapies, medicines, and vaccines to the masses. 4 Metaverse Stocks To Watch AbbVie Inc. Following that, we have AbbVie, a ... |
23,336 | 2022-06-11 00:00:00 UTC | AbbVie : Phase 2 Trial Of Epcoritamab Shows Clinically Meaningful Efficacy In Large B-cell Lymphoma | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-phase-2-trial-of-epcoritamab-shows-clinically-meaningful-efficacy-in-large-b-cell | null | null | (RTTNews) - AbbVie (ABBV) said results from phase 2 trial of investigational epcoritamab (DuoBody-CD3xCD20) in patients with Relapsed/Refractory Large B-cell Lymphoma showed clinically meaningful efficacy.
In the study, the nvestigational subcutaneous bispecific antibody epcoritamab demonstrated efficacy with durable r... | (RTTNews) - AbbVie (ABBV) said results from phase 2 trial of investigational epcoritamab (DuoBody-CD3xCD20) in patients with Relapsed/Refractory Large B-cell Lymphoma showed clinically meaningful efficacy. The companies remain committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of the... | (RTTNews) - AbbVie (ABBV) said results from phase 2 trial of investigational epcoritamab (DuoBody-CD3xCD20) in patients with Relapsed/Refractory Large B-cell Lymphoma showed clinically meaningful efficacy. The companies remain committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of the... | The companies remain committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy for a variety of hematologic malignancies, including an ongoing phase 3, open-label, randomized trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory diffuse large B-cell l... | (RTTNews) - AbbVie (ABBV) said results from phase 2 trial of investigational epcoritamab (DuoBody-CD3xCD20) in patients with Relapsed/Refractory Large B-cell Lymphoma showed clinically meaningful efficacy. Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The... |
23,337 | 2022-06-11 00:00:00 UTC | 2 Best Biotech Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-best-biotech-stocks-to-buy-right-now | null | null | The launch of quality healthcare services and products over the past several decades has had an overwhelmingly positive impact on society. That's because these goods and services can prevent or treat many chronic medical conditions, which has resulted in an improved quality of life for many patients.
Here are two estab... | And when AbbVie's U.S. patent for Humira expires in 2023, Keytruda will likely claim its spot as the overall best-selling drug in the world. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Kody Kester has positions in AbbVie, Amgen, and Merck & Co. That's because these goods and services can prevent or trea... | And when AbbVie's U.S. patent for Humira expires in 2023, Keytruda will likely claim its spot as the overall best-selling drug in the world. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Kody Kester has positions in AbbVie, Amgen, and Merck & Co. Amgen Amgen's (NASDAQ: AMGN) $131.5 billion market capitali... | See the 10 stocks *Stock Advisor returns as of June 2, 2022 Kody Kester has positions in AbbVie, Amgen, and Merck & Co. And when AbbVie's U.S. patent for Humira expires in 2023, Keytruda will likely claim its spot as the overall best-selling drug in the world. Amgen Amgen's (NASDAQ: AMGN) $131.5 billion market capitali... | And when AbbVie's U.S. patent for Humira expires in 2023, Keytruda will likely claim its spot as the overall best-selling drug in the world. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Kody Kester has positions in AbbVie, Amgen, and Merck & Co. This is because the stock's dividend payout ratio will be 4... |
23,338 | 2022-06-10 00:00:00 UTC | AbbVie : Data Shows Venclyxto/Venclexta Combination Sustained PFS In Chronic Lymphocytic Leukemia | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-data-shows-venclyxto-venclexta-combination-sustained-pfs-in-chronic-lymphocytic | null | null | (RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or CLL who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus obinutuzumab (... | (RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or CLL who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus obinutuzumab (... | (RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or CLL who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus obinutuzumab (... | (RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or CLL who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus obinutuzumab (... | It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. (RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leuke... |
23,339 | 2022-06-10 00:00:00 UTC | EXCLUSIVE-CVC explores $2 billion sale of software firm VelocityEHS -sources | ABBV | https://www.nasdaq.com/articles/exclusive-cvc-explores-%242-billion-sale-of-software-firm-velocityehs-sources | null | null | By Emma-Victoria Farr and Krystal Hu
June 10 (Reuters) - Private equity firm CVC Capital Partners is exploring a sale of VelocityEHS for as much as $2 billion, seeking to capitalize on a boom in demand for compliance software in the corporate world, three people familiar with the matter said.
CVC is working with U.S. i... | VelocityEHS serves more than 19,000 business customers across manufacturing, pharmaceutical and energy industries, including AbbVie ABBV.N and Chesapeake Energy CHK.O. CVC is working with U.S. investment bank William Blair on a sale process for VelocityEHS, which provides cloud-based applications to help businesses com... | VelocityEHS serves more than 19,000 business customers across manufacturing, pharmaceutical and energy industries, including AbbVie ABBV.N and Chesapeake Energy CHK.O. By Emma-Victoria Farr and Krystal Hu June 10 (Reuters) - Private equity firm CVC Capital Partners is exploring a sale of VelocityEHS for as much as $2 b... | VelocityEHS serves more than 19,000 business customers across manufacturing, pharmaceutical and energy industries, including AbbVie ABBV.N and Chesapeake Energy CHK.O. By Emma-Victoria Farr and Krystal Hu June 10 (Reuters) - Private equity firm CVC Capital Partners is exploring a sale of VelocityEHS for as much as $2 b... | VelocityEHS serves more than 19,000 business customers across manufacturing, pharmaceutical and energy industries, including AbbVie ABBV.N and Chesapeake Energy CHK.O. By Emma-Victoria Farr and Krystal Hu June 10 (Reuters) - Private equity firm CVC Capital Partners is exploring a sale of VelocityEHS for as much as $2 b... |
23,340 | 2022-06-10 00:00:00 UTC | 3 Dividend Stocks to Buy Now for 20 Years of Income Growth | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-now-for-20-years-of-income-growth | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividends can be an important source of income for investors. Consider that Warren Buffett earns more than $4 billion a year in dividend payments from his vast stock holdings, including more than $500 million from his position in Coca-Cola (NYSE:KO) alone, ... | Plus, AbbVie is a “Dividend King,” having raised its quarterly payout for 50 consecutive years, including when the company was part of medical-device firm Abbott Laboratories (NYSE:ABT). ABBV AbbVie $149.42 KMI Kinder Morgan $19.50 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading phar... | The combination of strong sales, stock gains, and dividend payments makes ABBV stock a definite buy. ABBV AbbVie $149.42 KMI Kinder Morgan $19.50 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading pharmaceutical company based in Chicago that is perhaps best known for its blockbuster med... | ABBV AbbVie $149.42 KMI Kinder Morgan $19.50 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading pharmaceutical company based in Chicago that is perhaps best known for its blockbuster medication Humira that is primarily used to treat arthritis and is the world’s bestselling prescription ... | ABBV AbbVie $149.42 KMI Kinder Morgan $19.50 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading pharmaceutical company based in Chicago that is perhaps best known for its blockbuster medication Humira that is primarily used to treat arthritis and is the world’s bestselling prescription ... |
23,341 | 2022-06-09 00:00:00 UTC | ABBV July 29th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-july-29th-options-begin-trading | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the July 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new July 29th contracts and identified one put and one call contract of particular interest.
The put contrac... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $145.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $4.35. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new July 29th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Consideri... |
23,342 | 2022-06-08 00:00:00 UTC | Could AbbVie Stock Help You Retire a Millionaire? | ABBV | https://www.nasdaq.com/articles/could-abbvie-stock-help-you-retire-a-millionaire | null | null | Building wealth for retirement is a lot easier when you own shares of companies that can keep growing for years and years without getting topped by rivals or otherwise swept away by the changing winds of the market. For example, mature businesses like AbbVie (NYSE: ABBV) are often especially favorable for retirement sa... | For example, mature businesses like AbbVie (NYSE: ABBV) are often especially favorable for retirement savings, due to their stable growth and demonstrated ability to prosper over time. Between the rising dividend payment, ongoing share buybacks, and earnings growth, it's entirely plausible that AbbVie stock could help ... | At its present yield, you'd need to invest more than $2.6 million in AbbVie shares to get a yearly dividend income of $100,000, which isn't exactly an amount of income that screams "I'm a millionaire." Between the rising dividend payment, ongoing share buybacks, and earnings growth, it's entirely plausible that AbbVie ... | The benefits of AbbVie's massive pipeline and constantly growing roster of medicines on the market are that investors can count on it to survive and grow over time while also paying out an ever-increasing quarterly dividend and pursuing share buybacks to pump up its stock price. At its present yield, you'd need to inve... | Given that it might be necessary to hold shares and wait for years, could a stake in AbbVie be enough to grow your investment into millions? At its present yield, you'd need to invest more than $2.6 million in AbbVie shares to get a yearly dividend income of $100,000, which isn't exactly an amount of income that scream... |
23,343 | 2022-06-07 00:00:00 UTC | What Stocks To Buy Today? 3 Biotech Stocks To Know | ABBV | https://www.nasdaq.com/articles/what-stocks-to-buy-today-3-biotech-stocks-to-know | null | null | 3 Top Biotech Stocks For Your June 2022 Watchlist
For investors looking for the most active stocks in the stock market now, biotech stocks could be a go-to. After all, companies across the industry are constantly providing key updates on their latest developmental pipeline advances. Aside from this, there would also be... | At the same time, major biotech stocks such as AbbVie (NYSE: ABBV) continue to make headway as well. On June 6, 2022, the company announced that the U.S. Food and Drug Administration (FDA) has approved Priorix for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. Furthermore, the ... | At the same time, major biotech stocks such as AbbVie (NYSE: ABBV) continue to make headway as well. Biotech Stocks To Watch This Week GlaxoSmithKline plc (NYSE: GSK) Pfizer Inc. (NYSE: PFE) Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) GlaxoSmithKline plc. Source: TD Ameritrade TOS [Read More] 5 Cybersecurity Stocks F... | At the same time, major biotech stocks such as AbbVie (NYSE: ABBV) continue to make headway as well. 3 Top Biotech Stocks For Your June 2022 Watchlist For investors looking for the most active stocks in the stock market now, biotech stocks could be a go-to. The expansion adds to the initial investment of $450 million i... | At the same time, major biotech stocks such as AbbVie (NYSE: ABBV) continue to make headway as well. Among its 2021 milestones, it had 8 regulatory approvals and 13 Phase 3 study starts. The expansion adds to the initial investment of $450 million in phase one to build a 400,000-square-foot production facility and furt... |
23,344 | 2022-06-07 00:00:00 UTC | Warren Buffett Just Sold This Popular Stock -- Should You? | ABBV | https://www.nasdaq.com/articles/warren-buffett-just-sold-this-popular-stock-should-you | null | null | When it comes to success with investing, Warren Buffett is hard to one-up, to say the least. But even if you can't outperform him, you just might be able to get (approximately) similar returns by copying his trades or at least dodge some problems by selling when he does.
On that note, in the first quarter of this year,... | AbbVie has a pair of other medicines it claims should be able to recoup Humira's market share and total revenue so that the business can keep growing, but Buffett might be skeptical of this plan. On that note, in the first quarter of this year, the Oracle of Omaha's company, Berkshire Hathaway (NYSE: BRK.A, BRK.B), sol... | On that note, in the first quarter of this year, the Oracle of Omaha's company, Berkshire Hathaway (NYSE: BRK.A, BRK.B), sold 100% of his three million AbbVie (NYSE: ABBV) shares with a total value of around $410 million. AbbVie has a pair of other medicines it claims should be able to recoup Humira's market share and ... | The largest and last nail in the coffin for Buffett's AbbVie holdings was probably declining revenue from Humira, the company's blockbuster psoriatic arthritis drug and one of the best-selling drugs of all time. AbbVie has a pair of other medicines it claims should be able to recoup Humira's market share and total reve... | On that note, in the first quarter of this year, the Oracle of Omaha's company, Berkshire Hathaway (NYSE: BRK.A, BRK.B), sold 100% of his three million AbbVie (NYSE: ABBV) shares with a total value of around $410 million. For the uninitiated, AbbVie is among the biggest pharmaceutical companies in the world by market c... |
23,345 | 2022-06-07 00:00:00 UTC | Surprising Analyst 12-Month Target For SDY | ABBV | https://www.nasdaq.com/articles/surprising-analyst-12-month-target-for-sdy | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Dividend ETF (Symbol: ... | SPDR S&P Dividend ETF SDY $127.05 $140.50 10.59% Cardinal Health, Inc. CAH $53.74 $60.88 13.28% AbbVie Inc ABBV $146.53 $165.00 12.60% SEI Investments Co SEIC $57.60 $63.80 10.76% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SDY's un... | Three of SDY's underlying holdings with notable upside to their analyst target prices are Cardinal Health, Inc. (Symbol: CAH), AbbVie Inc (Symbol: ABBV), and SEI Investments Co (Symbol: SEIC). Similarly, ABBV has 12.60% upside from the recent share price of $146.53 if the average analyst target price of $165.00/share i... | Similarly, ABBV has 12.60% upside from the recent share price of $146.53 if the average analyst target price of $165.00/share is reached, and analysts on average are expecting SEIC to reach a target price of $63.80/share, which is 10.76% above the recent price of $57.60. Three of SDY's underlying holdings with notable ... | SPDR S&P Dividend ETF SDY $127.05 $140.50 10.59% Cardinal Health, Inc. CAH $53.74 $60.88 13.28% AbbVie Inc ABBV $146.53 $165.00 12.60% SEI Investments Co SEIC $57.60 $63.80 10.76% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SDY's un... |
23,346 | 2022-06-06 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-2 | null | null | AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session. This change lagged the S&P 500's daily gain of 0.31%. Meanwhile, the Dow gained 0.05%, and the Nasdaq, a tech-heavy index, added 0.14%.
Prior to today's trading, shares of the drugmaker had lost 3.7% over the p... | AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie is currently a Zacks Rank #3 (Hold). AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. |
23,347 | 2022-06-06 00:00:00 UTC | The Health Care Select Sector SPDR Fund Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/the-health-care-select-sector-spdr-fund-experiences-big-inflow-0 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $908.7 million dollar inflow -- that's a 2.4% increase week over week in outstanding units (from 2... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Danaher Corp (Symbol: DHR) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Cha... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Danaher Corp (Symbol: DHR) is higher by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Danaher Corp (Symbol: DHR) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Cha... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Danaher Corp (Symbol: DHR) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Cha... |
23,348 | 2022-06-05 00:00:00 UTC | 3 Great Dividend Stocks to Buy in June | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-in-june | null | null | Guess which stocks tend to perform better than most during market downturns? If your answer is solid dividend stocks, you're exactly right.
We asked three Motley Fool contributors to pick great dividend stocks to buy in June. Here's why they chose AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS).
I... | Here's why they chose AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS). Keith Speights (AbbVie): Make no mistake about it: AbbVie is a king. AbbVie has been a solid winner so far in 2022 as well. | Keith Speights has positions in AbbVie, Health Care SPDR, Pfizer, and Viatris Inc. Prosper Junior Bakiny has no position in any of the stocks mentioned. Here's why they chose AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS). Keith Speights (AbbVie): Make no mistake about it: AbbVie is a king. | Here's why they chose AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS). Keith Speights (AbbVie): Make no mistake about it: AbbVie is a king. AbbVie has been a solid winner so far in 2022 as well. | Here's why they chose AbbVie (NYSE: ABBV), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS). Keith Speights (AbbVie): Make no mistake about it: AbbVie is a king. AbbVie has been a solid winner so far in 2022 as well. |
23,349 | 2022-06-05 00:00:00 UTC | Can the Best-Selling Drugs of 2021 Repeat Their Performance? | ABBV | https://www.nasdaq.com/articles/can-the-best-selling-drugs-of-2021-repeat-their-performance | null | null | Investors looking for stocks that can put up big gains know that pharmaceutical sales can make it happen. Two out of three of the world's top-selling drugs weren't even available in 2020.
Last year, in the U.S. alone, prescription drug sales reached $577 billion, and that was 7.7% more than a year earlier. A substantia... | Humira: $20.7 billion Humira, an anti-inflammatory drug from AbbVie (NYSE: ABBV) had been in the top spot for years. AbbVie hasn't provided forward guidance for Humira sales in 2022, but we can probably expect one more year of price increases in the U.S. market. Recent authorization from the U.S. Food and Drug Administ... | Humira: $20.7 billion Humira, an anti-inflammatory drug from AbbVie (NYSE: ABBV) had been in the top spot for years. AbbVie hasn't provided forward guidance for Humira sales in 2022, but we can probably expect one more year of price increases in the U.S. market. Merck's drug racked up $17.2 billion in sales last year, ... | Humira: $20.7 billion Humira, an anti-inflammatory drug from AbbVie (NYSE: ABBV) had been in the top spot for years. AbbVie hasn't provided forward guidance for Humira sales in 2022, but we can probably expect one more year of price increases in the U.S. market. Last year, in the U.S. alone, prescription drug sales rea... | Humira: $20.7 billion Humira, an anti-inflammatory drug from AbbVie (NYSE: ABBV) had been in the top spot for years. AbbVie hasn't provided forward guidance for Humira sales in 2022, but we can probably expect one more year of price increases in the U.S. market. Unlike Pfizer and BioNTech, Moderna expects sales of its ... |
23,350 | 2022-06-04 00:00:00 UTC | 2 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/2-top-dividend-kings-to-buy-for-the-long-haul-1 | null | null | Trusted dividend stocks tend to both perform well compared to the broader market and consistently raise their dividends, regardless of what's going on in the world.
The most respected dividend stocks are those that have increased their payouts for at least 50 consecutive years. These stocks are called Dividend Kings. T... | Two of the 39 Dividend Kings are pharma stocks Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). The company possessed more than a dozen blockbusters in its product portfolio in 2021, including its mega-blockbuster immunology drug Stelara, antipsychotic drug franchise Invega, and a cancer drug co-owned with AbbVie... | Two of the 39 Dividend Kings are pharma stocks Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). The company possessed more than a dozen blockbusters in its product portfolio in 2021, including its mega-blockbuster immunology drug Stelara, antipsychotic drug franchise Invega, and a cancer drug co-owned with AbbVie... | Two of the 39 Dividend Kings are pharma stocks Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of April 27, 2022 Kody Kester has positions in AbbVie and Johnson & Johnson. The company possessed more than a dozen blockbusters in its product portfolio in 2021, including ... | Two of the 39 Dividend Kings are pharma stocks Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). The company possessed more than a dozen blockbusters in its product portfolio in 2021, including its mega-blockbuster immunology drug Stelara, antipsychotic drug franchise Invega, and a cancer drug co-owned with AbbVie... |
23,351 | 2022-06-03 00:00:00 UTC | Best Health Care Stocks To Invest In Today? 3 In Focus | ABBV | https://www.nasdaq.com/articles/best-health-care-stocks-to-invest-in-today-3-in-focus | null | null | 3 Health Care Stocks For Your June 2022 Watchlist
With all the back-and-forth in the stock market recently, investors may be looking for more defensive stocks to jump on. Should that be the case, health care stocks would be among the key groups to consider. After all, the industry produces a vast array of life-improvin... | As of earlier today, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) received a positive update on their leukemia drug Imbruvica. Turning Point Therapeutics’ lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting the ROS1 and NTRK oncogenic drivers of no... | As of earlier today, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) received a positive update on their leukemia drug Imbruvica. Health Care Stocks To Buy [Or Sell] Right Now Bristol-Myers Squibb Company (NYSE: BMY) Teladoc Health Inc. (NYSE: TDOC) Moderna Inc. (NASDAQ: MRNA) Bristol-Myers Squibb Co Bristol Myer... | As of earlier today, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) received a positive update on their leukemia drug Imbruvica. Health Care Stocks To Buy [Or Sell] Right Now Bristol-Myers Squibb Company (NYSE: BMY) Teladoc Health Inc. (NYSE: TDOC) Moderna Inc. (NASDAQ: MRNA) Bristol-Myers Squibb Co Bristol Myer... | As of earlier today, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) received a positive update on their leukemia drug Imbruvica. Should that be the case, health care stocks would be among the key groups to consider. Source: TD Ameritrade TOS [Read More] Stock Market Today: Dow Jones, S&P 500 Falter; Okta Stock S... |
23,352 | 2022-06-03 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -3.6%, compared to the Zacks S&P 500 composite's +0.... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals indu... | Last Reported Results and Surprise History AbbVie reported revenues of $13.54 billion in the last reported quarter, representing a year-over-year change of +4.1%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbV... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, whi... | For the next fiscal year, the consensus earnings estimate of $11.86 indicates a change of -15.4% from what AbbVie is expected to report a year ago. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, ha... |
23,353 | 2022-06-03 00:00:00 UTC | J&J, AbbVie cancer drug significantly slows progression of rare lymphoma -study | ABBV | https://www.nasdaq.com/articles/jj-abbvie-cancer-drug-significantly-slows-progression-of-rare-lymphoma-study | null | null | By Michael Erman
June 3 (Reuters) - Johnson & Johnson JNJ.N and AbbVie's ABBV.N big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Fr... | By Michael Erman June 3 (Reuters) - Johnson & Johnson JNJ.N and AbbVie's ABBV.N big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Fr... | By Michael Erman June 3 (Reuters) - Johnson & Johnson JNJ.N and AbbVie's ABBV.N big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Fr... | By Michael Erman June 3 (Reuters) - Johnson & Johnson JNJ.N and AbbVie's ABBV.N big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Fr... | By Michael Erman June 3 (Reuters) - Johnson & Johnson JNJ.N and AbbVie's ABBV.N big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Fr... |
23,354 | 2022-06-02 00:00:00 UTC | Bristol Myers, J&J drugs reduce COVID death rates in NIH study | ABBV | https://www.nasdaq.com/articles/bristol-myers-jj-drugs-reduce-covid-death-rates-in-nih-study | null | null | Adds background and details
June 2 (Reuters) - A late-stage study of two rheumatoid arthritis drugs from Bristol Myers Squibb BMY.N and Johnson & Johnson JNJ.N showed a significant drop in deaths among hospitalized COVID patients, a U.S. health agency said on Thursday.
However, both the drugs failed to meet the main go... | (https://reut.rs/3aDOHLZ) The trial was testing the two drugs, along with AbbVie's ABBV.N experimental candidate cenicriviroc, to treat an overactive immune response called "cytokine storm" seen in certain patients with moderate-to-severe COVID-19. However, both the drugs failed to meet the main goal of speeding up rec... | (https://reut.rs/3aDOHLZ) The trial was testing the two drugs, along with AbbVie's ABBV.N experimental candidate cenicriviroc, to treat an overactive immune response called "cytokine storm" seen in certain patients with moderate-to-severe COVID-19. Adds background and details June 2 (Reuters) - A late-stage study of tw... | (https://reut.rs/3aDOHLZ) The trial was testing the two drugs, along with AbbVie's ABBV.N experimental candidate cenicriviroc, to treat an overactive immune response called "cytokine storm" seen in certain patients with moderate-to-severe COVID-19. Adds background and details June 2 (Reuters) - A late-stage study of tw... | (https://reut.rs/3aDOHLZ) The trial was testing the two drugs, along with AbbVie's ABBV.N experimental candidate cenicriviroc, to treat an overactive immune response called "cytokine storm" seen in certain patients with moderate-to-severe COVID-19. Adds background and details June 2 (Reuters) - A late-stage study of tw... |
23,355 | 2022-06-01 00:00:00 UTC | AbbVie Presents Positive Results From Phase 3 Trials Of Upadacitinib In Axial Spondyloarthritis | ABBV | https://www.nasdaq.com/articles/abbvie-presents-positive-results-from-phase-3-trials-of-upadacitinib-in-axial | null | null | (RTTNews) - AbbVie (ABBV) said that it presented full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ), an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis or nr-axSpA and patients with treatment-refractory active ankylosing spondylitis... | (RTTNews) - AbbVie (ABBV) said that it presented full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ), an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis or nr-axSpA and patients with treatment-refractory active ankylosing spondylitis... | (RTTNews) - AbbVie (ABBV) said that it presented full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ), an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis or nr-axSpA and patients with treatment-refractory active ankylosing spondylitis... | (RTTNews) - AbbVie (ABBV) said that it presented full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ), an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis or nr-axSpA and patients with treatment-refractory active ankylosing spondylitis... | (RTTNews) - AbbVie (ABBV) said that it presented full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ), an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis or nr-axSpA and patients with treatment-refractory active ankylosing spondylitis... |
23,356 | 2022-06-01 00:00:00 UTC | 1 Green Flag for AbbVie in 2022 and 1 Red Flag | ABBV | https://www.nasdaq.com/articles/1-green-flag-for-abbvie-in-2022-and-1-red-flag | null | null | If there was one area of optimism in this market since the start of the year, I'd have to say it was healthcare. The S&P 500 healthcare sector grew 2.7% -- until the first week of April hit. Then the bottom dropped out. Yet, year-to-date the healthcare sector is still down only 6% in 2022 vs. a 13.5% decline for the br... | In the case of AbbVie (NYSE: ABBV), its shares have dropped 15.5% since the start of the year, due not only to the broader market decline but also because of challenges facing a top-selling product. In a very short time span, the drugs have become two of the top revenue generators for AbbVie and helped solidify the com... | Red Flag: sales decline of top-selling drug Humira The biggest problem facing AbbVie right now is how to make up for a decline in sales of its top-selling drug, Humira. Now, AbbVie's stock could be enticing after its 15% decline in share price for a company with enough depth to make it a top pick in an uncertain market... | Red Flag: sales decline of top-selling drug Humira The biggest problem facing AbbVie right now is how to make up for a decline in sales of its top-selling drug, Humira. AbbVie ended the year with an increase of 3.7% in Humira sales over full-year 2020, but that number would have been stronger if not for a decline of 12... | In the case of AbbVie (NYSE: ABBV), its shares have dropped 15.5% since the start of the year, due not only to the broader market decline but also because of challenges facing a top-selling product. Now, AbbVie's stock could be enticing after its 15% decline in share price for a company with enough depth to make it a t... |
23,357 | 2022-06-01 00:00:00 UTC | My 3 Favorite Dividend Stocks to Buy in June | ABBV | https://www.nasdaq.com/articles/my-3-favorite-dividend-stocks-to-buy-in-june | null | null | Forget the old adage "sell and May and go away." Any time is a good time to buy dividend stocks. That's true even when the stock market is highly volatile -- as it is now.
There are two important prerequisites, though. First, you need to have a long-term mindset. Even the best dividend stocks can fall over the short te... | This discounted valuation is largely due to investors' concerns about AbbVie's top-selling drug Humira losing U.S. patent exclusivity next year. Indeed, market research firm EvaluatePharma predicts that AbbVie will be the biggest drugmaker in the world by 2028 based on prescription drug sales. AbbVie AbbVie (NYSE: ABBV... | Devon Energy Unlike Brookfield Renewable and AbbVie, Devon Energy (NYSE: DVN) is an indisputably massive winner so far in 2022. See the 10 stocks *Stock Advisor returns as of April 27, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation, Brookfield Renewable Partners L.P., and Devon Energy. Ab... | AbbVie has increased its dividend for 50 consecutive years, which qualifies the company as a member of the elite group of stocks known as Dividend Kings. See the 10 stocks *Stock Advisor returns as of April 27, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation, Brookfield Renewable Partners ... | See the 10 stocks *Stock Advisor returns as of April 27, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation, Brookfield Renewable Partners L.P., and Devon Energy. AbbVie AbbVie (NYSE: ABBV) stands out as another company that is built to last. AbbVie has increased its dividend for 50 consecuti... |
23,358 | 2022-05-30 00:00:00 UTC | The 3 Best Performing ETFs Money Can Buy in 2022 | ABBV | https://www.nasdaq.com/articles/the-3-best-performing-etfs-money-can-buy-in-2022 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
These best performing ETFs so far this year could see further traction as investors return to the markets.
First Trust Morningstar Dividend Leaders Index Fund (FDL): This ETF focuses on dividend growth consistency when choosing stocks.
WisdomTree U.S. High ... | Among them are AT&T (NYSE:T), Abbvie (NYSE:ABBV), Chevron (NYSE:CVX), Verizon Communications (NYSE:VZ), and Pfizer (NYSE:PFE). Source: Maxx-Studio/ShutterStock.com Investors are scrambling to find the best performing ETFs (exchange-traded funds) in whgat has proven so far to be a tough year. Moreover, defensive ETFs t... | Among them are AT&T (NYSE:T), Abbvie (NYSE:ABBV), Chevron (NYSE:CVX), Verizon Communications (NYSE:VZ), and Pfizer (NYSE:PFE). FDL First Trust Morningstar Dividend Leaders Index Fund $39.18 DHS WisdomTree U.S. High Dividend Fund $90.83 RYE Invesco S&P 500 Equal Weight Energy ETF $77.73 First Trust Morningstar Dividend... | Among them are AT&T (NYSE:T), Abbvie (NYSE:ABBV), Chevron (NYSE:CVX), Verizon Communications (NYSE:VZ), and Pfizer (NYSE:PFE). FDL First Trust Morningstar Dividend Leaders Index Fund $39.18 DHS WisdomTree U.S. High Dividend Fund $90.83 RYE Invesco S&P 500 Equal Weight Energy ETF $77.73 First Trust Morningstar Dividend... | Among them are AT&T (NYSE:T), Abbvie (NYSE:ABBV), Chevron (NYSE:CVX), Verizon Communications (NYSE:VZ), and Pfizer (NYSE:PFE). Moreover, defensive ETFs that hold stocks with high dividend payouts, such as utilities, real estate, healthcare, and consumer staples, have also attracted significant net inflows this year. W... |
23,359 | 2022-05-27 00:00:00 UTC | Noteworthy Friday Option Activity: QCOM, MCD, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-qcom-mcd-abbv | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Qualcomm Inc (Symbol: QCOM), where a total volume of 43,535 contracts has been traded thus far today, a contract volume which is representative of approximately 4.4 million underlying shares (given that ever... | Especially high volume was seen for the $165 strike call option expiring August 19, 2022, with 10,112 contracts trading so far today, representing approximately 1.0 million underlying shares of ABBV. Below is a chart showing MCD's trailing twelve month trading history, with the $265 strike highlighted in orange: And Ab... | Below is a chart showing MCD's trailing twelve month trading history, with the $265 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 30,352 contracts, representing approximately 3.0 million underlying shares or approximately 40.7% of ABBV's average daily trading volume over the ... | Below is a chart showing MCD's trailing twelve month trading history, with the $265 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 30,352 contracts, representing approximately 3.0 million underlying shares or approximately 40.7% of ABBV's average daily trading volume over the ... | Especially high volume was seen for the $165 strike call option expiring August 19, 2022, with 10,112 contracts trading so far today, representing approximately 1.0 million underlying shares of ABBV. Below is a chart showing MCD's trailing twelve month trading history, with the $265 strike highlighted in orange: And Ab... |
23,360 | 2022-05-27 00:00:00 UTC | HDV, YCS: Big ETF Inflows | ABBV | https://www.nasdaq.com/articles/hdv-ycs%3A-big-etf-inflows | null | null | Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core High Dividend ETF, which added 19,800,000 units, or a 20.2% increase week over week. Among the largest underlying components of HDV, in morning trading today Exxon Mobil is tr... | Among the largest underlying components of HDV, in morning trading today Exxon Mobil is trading flat, and Abbvie is lower by about 1.2%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core High Dividend ETF, which added 19,800,... | Among the largest underlying components of HDV, in morning trading today Exxon Mobil is trading flat, and Abbvie is lower by about 1.2%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core High Dividend ETF, which added 19,800,... | Among the largest underlying components of HDV, in morning trading today Exxon Mobil is trading flat, and Abbvie is lower by about 1.2%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core High Dividend ETF, which added 19,800,... | Among the largest underlying components of HDV, in morning trading today Exxon Mobil is trading flat, and Abbvie is lower by about 1.2%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core High Dividend ETF, which added 19,800,... |
23,361 | 2022-05-26 00:00:00 UTC | SPY, ABBV, ABT, ACN: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/spy-abbv-abt-acn%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $1 inflow -- that's a 0.3% increase week over week in outstanding units (from 90,0,8,80,,000 to 90,3,9,80,,000). Am... | Among the largest underlying components of SPY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Accenture plc (Symbol: ACN) is up by about 2.8%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of SPY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Accenture plc (Symbol: ACN) is up by about 2.8%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of SPY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Accenture plc (Symbol: ACN) is up by about 2.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... | Among the largest underlying components of SPY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Accenture plc (Symbol: ACN) is up by about 2.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... |
23,362 | 2022-05-26 00:00:00 UTC | Best Health Care Stocks To Invest In 2022? 3 Names To Watch | ABBV | https://www.nasdaq.com/articles/best-health-care-stocks-to-invest-in-2022-3-names-to-watch | null | null | Are These The Best Health Care Stocks To Have On Your June 2022 Watchlist?
As talks of inflation and a possible recession dominate the headlines, investors may choose to rotate towards more defensive positions. Hence, health care stocks could be worth looking at. After all, health care stocks encompass a broad range of... | “Advanced Parkinson’s disease causes unrelenting challenges and uncertainty for patients and caregivers worldwide,” said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. Health Care Stocks To Watch Right Now Thermo Fisher Scientific Inc. (NYSE: TMO) Biohaven Pharma... | Health Care Stocks To Watch Right Now Thermo Fisher Scientific Inc. (NYSE: TMO) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) AbbVie Inc (NYSE: ABBV) Thermo Fisher Thermo Fisher is a health care company that develops, manufactures, and sells a range of products. [Read More] Stock Market Today: Dow Jones, S&P 500 ... | Health Care Stocks To Watch Right Now Thermo Fisher Scientific Inc. (NYSE: TMO) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) AbbVie Inc (NYSE: ABBV) Thermo Fisher Thermo Fisher is a health care company that develops, manufactures, and sells a range of products. [Read More] Stock Market Today: Dow Jones, S&P 500 ... | If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa (CD/LD) prodrugs for the treatment of advanced Parkinson’s disease. Health Care Stocks To Watch Right Now Thermo Fisher Scientific Inc. (NYSE: TMO) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) AbbVie Inc (N... |
23,363 | 2022-05-26 00:00:00 UTC | Amgen (AMGN) Ahead of Industry This Year So Far: What's Next? | ABBV | https://www.nasdaq.com/articles/amgen-amgn-ahead-of-industry-this-year-so-far%3A-whats-next | null | null | Amgen has a diverse and growing portfolio of medicines in large therapeutic categories that it expects will help it drive growth through the end of the decade despite a declining pricing environment.
Amgen AMGN stock has risen 12.4% this year so far against a decrease of 24.5% for the industry.
Image Source: Zacks Inv... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... |
23,364 | 2022-05-26 00:00:00 UTC | 7 High-Yield Retirement Stocks to Buy for Your Nest Egg | ABBV | https://www.nasdaq.com/articles/7-high-yield-retirement-stocks-to-buy-for-your-nest-egg | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
These seven high-yield retirement stocks to buy are among the top picks to build a retirement portfolio that will provide a stable income.
Amcor (AMCR): Is a global leader in developing and producing responsible packaging.
3M Company (MMM): This conglomerat... | 7 Retirement Stocks to Buy to Turbocharge Your Savings Here are my top seven high-yield retirement stocks to buy for your nest egg: Ticker Company Price AMCR Amcor plc $13.20 MMM 3M Company $147.98 ABBV AbbVie Inc. $151.93 CAH Cardinal Health, Inc. $58.07 CVX Chevron Corporation $177.14 XOM Exxon Mobil Corporation $97.... | 7 Retirement Stocks to Buy to Turbocharge Your Savings Here are my top seven high-yield retirement stocks to buy for your nest egg: Ticker Company Price AMCR Amcor plc $13.20 MMM 3M Company $147.98 ABBV AbbVie Inc. $151.93 CAH Cardinal Health, Inc. $58.07 CVX Chevron Corporation $177.14 XOM Exxon Mobil Corporation $97.... | 7 Retirement Stocks to Buy to Turbocharge Your Savings Here are my top seven high-yield retirement stocks to buy for your nest egg: Ticker Company Price AMCR Amcor plc $13.20 MMM 3M Company $147.98 ABBV AbbVie Inc. $151.93 CAH Cardinal Health, Inc. $58.07 CVX Chevron Corporation $177.14 XOM Exxon Mobil Corporation $97.... | 7 Retirement Stocks to Buy to Turbocharge Your Savings Here are my top seven high-yield retirement stocks to buy for your nest egg: Ticker Company Price AMCR Amcor plc $13.20 MMM 3M Company $147.98 ABBV AbbVie Inc. $151.93 CAH Cardinal Health, Inc. $58.07 CVX Chevron Corporation $177.14 XOM Exxon Mobil Corporation $97.... |
23,365 | 2022-05-26 00:00:00 UTC | 3 Healthcare Stocks You Can Buy and Hold for the Next Decade | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-you-can-buy-and-hold-for-the-next-decade-0 | null | null | It's exciting to add new stocks to your portfolio or adjust positions. But it's also nice to own a handful of stocks that you can buy and hold on to for a long time -- like a decade or longer. You know that you can count on them for leadership in their market and earnings growth. Eventually, that should translate into ... | AbbVie The bad news for pharmaceutical company AbbVie (NYSE: ABBV) is that revenue from its blockbuster immunology drug Humira is on the decline. But here's the good news: AbbVie has other drugs that may compensate. AbbVie has said it expects combined peak sales of two other immunology treatments -- Skyrizi and Rinvoq ... | AbbVie has said it expects combined peak sales of two other immunology treatments -- Skyrizi and Rinvoq -- to top Humira's peak revenue. AbbVie The bad news for pharmaceutical company AbbVie (NYSE: ABBV) is that revenue from its blockbuster immunology drug Humira is on the decline. But here's the good news: AbbVie has ... | AbbVie The bad news for pharmaceutical company AbbVie (NYSE: ABBV) is that revenue from its blockbuster immunology drug Humira is on the decline. But here's the good news: AbbVie has other drugs that may compensate. AbbVie has said it expects combined peak sales of two other immunology treatments -- Skyrizi and Rinvoq ... | AbbVie The bad news for pharmaceutical company AbbVie (NYSE: ABBV) is that revenue from its blockbuster immunology drug Humira is on the decline. But here's the good news: AbbVie has other drugs that may compensate. AbbVie has said it expects combined peak sales of two other immunology treatments -- Skyrizi and Rinvoq ... |
23,366 | 2022-05-25 00:00:00 UTC | SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal | ABBV | https://www.nasdaq.com/articles/springworks-swtx-down-despite-desmoid-tumors-study-meeting-goal | null | null | SpringWorks Therapeutics, Inc. SWTX announced the phase III DeFi study, which evaluated its investigational gamma-secretase inhibitor, nirogacestat, for treating adult patients with progressing desmoid tumors, has met the primary and all key secondary endpoints.
Data from the study showed that treatment with nirogacest... | SpringWorks is also planning to evaluate nirogacestat in combination with Seagen’s investigational monoclonal antibody targeting BCMA – SEA-BCMA and AbbVie’s ABBV investigational CD3 bispecific antibody directed against BCMA, ABBV-383 for treating relapsed or refractory multiple myeloma. Last December, SpringWorks ente... | SpringWorks is also planning to evaluate nirogacestat in combination with Seagen’s investigational monoclonal antibody targeting BCMA – SEA-BCMA and AbbVie’s ABBV investigational CD3 bispecific antibody directed against BCMA, ABBV-383 for treating relapsed or refractory multiple myeloma. Last December, SpringWorks ente... | SpringWorks is also planning to evaluate nirogacestat in combination with Seagen’s investigational monoclonal antibody targeting BCMA – SEA-BCMA and AbbVie’s ABBV investigational CD3 bispecific antibody directed against BCMA, ABBV-383 for treating relapsed or refractory multiple myeloma. Last December, SpringWorks ente... | SpringWorks is also planning to evaluate nirogacestat in combination with Seagen’s investigational monoclonal antibody targeting BCMA – SEA-BCMA and AbbVie’s ABBV investigational CD3 bispecific antibody directed against BCMA, ABBV-383 for treating relapsed or refractory multiple myeloma. Last December, SpringWorks ente... |
23,367 | 2022-05-25 00:00:00 UTC | 2 Dividend Kings That Are Soundly Beating the Market in 2022 | ABBV | https://www.nasdaq.com/articles/2-dividend-kings-that-are-soundly-beating-the-market-in-2022 | null | null | Are you not sure about where to invest right now? Dividend stocks can be a great place to start looking. Their financials are generally sound, and they can enable you to collect some recurring cash flow while you hang on to your investment. And at a time when investors have been looking for safety, some of them have al... | The company's dividend-increasing streak goes back 50 years if you include when it was part of Abbott Laboratories; AbbVie spun off in 2013, and has been making its own regular rate hikes since then. While top-selling inflammation drug Humira generated $4.7 billion for the company through the first three months of 2022... | AbbVie's broad business can provide some solid stability at a time when other less-diversified companies struggle. A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Group (NYSE: MO). AbbVie AbbVie is a top healthcare stock that yields 3.7% annually, which is ... | It would take a $26,800 investment in the stock to generate $1,000 in annual dividend income from AbbVie at its current rate. A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Group (NYSE: MO). AbbVie AbbVie is a top healthcare stock that yields 3.7% annually... | It would take a $26,800 investment in the stock to generate $1,000 in annual dividend income from AbbVie at its current rate. And like with AbbVie, that dividend income will likely increase over the years. A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Gro... |
23,368 | 2022-05-25 00:00:00 UTC | Teva, Allergan reach $161.5 million opioid settlement with West Virginia | ABBV | https://www.nasdaq.com/articles/teva-allergan-reach-%24161.5-million-opioid-settlement-with-west-virginia | null | null | By Dietrich Knauth
May 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday.
The agreement is the largest state-... | By Dietrich Knauth May 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday. The agreement is the largest state-... | By Dietrich Knauth May 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday. The agreement is the largest state-... | By Dietrich Knauth May 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday. The agreement is the largest state-... | By Dietrich Knauth May 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday. "This is a great day for West Virgi... |
23,369 | 2022-05-25 00:00:00 UTC | 7 Retirement Stocks to Buy to Turbocharge Your Savings | ABBV | https://www.nasdaq.com/articles/7-retirement-stocks-to-buy-to-turbocharge-your-savings | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Buying quality retirement stocks can provide both safety and growth to keep savings goals on track
AbbVie (ABBV): With revenue concerns abating, it’s time to take a fresh look at this dividend king.
Amgen (AMGN): This biotech giant has an ideal combination ... | My InvestorPlace colleague Josh Enomoto also reminded investors that AbbVie is likely to benefit from its acquisition of Allergan, which put Botox into the company’s product portfolio. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying quality retirement stocks can provide both safety and growth to k... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying quality retirement stocks can provide both safety and growth to keep savings goals on track AbbVie (ABBV): With revenue concerns abating, it’s time to take a fresh look at this dividend king. Ticker Company Current Price ABBV AbbVie $149.11 AMGN Amge... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying quality retirement stocks can provide both safety and growth to keep savings goals on track AbbVie (ABBV): With revenue concerns abating, it’s time to take a fresh look at this dividend king. Ticker Company Current Price ABBV AbbVie $149.11 AMGN Amge... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buying quality retirement stocks can provide both safety and growth to keep savings goals on track AbbVie (ABBV): With revenue concerns abating, it’s time to take a fresh look at this dividend king. Ticker Company Current Price ABBV AbbVie $149.11 AMGN Amge... |
23,370 | 2022-05-24 00:00:00 UTC | 3 Great Dividend Stocks to Buy Now and Hold | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-now-and-hold | null | null | Today’s episode of Full Court Finance at Zacks breaks down the broader economic forces behind the current market turmoil. The episode then explores three strong dividend-paying stocks from three different areas of the economy that investors might want to consider buying during the market downturn and holding for the lo... | AbbVie ABBV is a pharmaceutical power that diversified through its huge Allergan acquisition in 2020. AbbVie topped our Q1 earnings estimates and the stock has managed to climb 13% in 2022 to outpace its industry and the market’s big fall. Plus, Wall Street is high on ABBV and its 3.8% dividend yield is rather enticing... | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie ABBV is a pharmaceutical power that diversified through its huge Allergan acquisition in 2020. AbbVie topped our Q1 earnings estimates and the stock has managed to climb 13% in 2022 to outpace its industry and the market’s big fall. | AbbVie ABBV is a pharmaceutical power that diversified through its huge Allergan acquisition in 2020. AbbVie topped our Q1 earnings estimates and the stock has managed to climb 13% in 2022 to outpace its industry and the market’s big fall. Plus, Wall Street is high on ABBV and its 3.8% dividend yield is rather enticing... | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie ABBV is a pharmaceutical power that diversified through its huge Allergan acquisition in 2020. AbbVie topped our Q1 earnings estimates and the stock has managed to climb 13% in 2022 to outpace its industry and the market’s big fall. |
23,371 | 2022-05-24 00:00:00 UTC | Why High Dividend ETFs are Beating the Market | ABBV | https://www.nasdaq.com/articles/why-high-dividend-etfs-are-beating-the-market | null | null | Dividend paying stocks are always popular with investors since about a third of S&P 500’s total returns since 1960 can be attributed to dividends. Over the past three decades, S&P 500 returns including dividends exceeded the index’s price returns by more than double, per BlackRock.
In the current market environment of ... | Exxon Mobil (XOM) and AbbVie (ABBV) are its top holdings. AT&T (T) and AbbVie are its top holdings. AbbVie Inc. (ABBV): Free Stock Analysis Report | Exxon Mobil (XOM) and AbbVie (ABBV) are its top holdings. AT&T (T) and AbbVie are its top holdings. AbbVie Inc. (ABBV): Free Stock Analysis Report | Exxon Mobil (XOM) and AbbVie (ABBV) are its top holdings. AT&T (T) and AbbVie are its top holdings. AbbVie Inc. (ABBV): Free Stock Analysis Report | Exxon Mobil (XOM) and AbbVie (ABBV) are its top holdings. AT&T (T) and AbbVie are its top holdings. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,372 | 2022-05-24 00:00:00 UTC | These 2 Numbers Could Spell Trouble for AbbVie Stock | ABBV | https://www.nasdaq.com/articles/these-2-numbers-could-spell-trouble-for-abbvie-stock | null | null | AbbVie (NYSE: ABBV) investors might have a reason to start sweating. After a somewhat weak first quarter, the biopharma company's near future looks like it'll be one with a bit less revenue than expected.
That's something that would always be a problem, but in this case, the issue is a bit more pressing than usual. Bef... | That means that the pair will, in theory, be able to contest the markets that Humira is getting boxed out of by biosimilars, thereby maintaining AbbVie's base of revenue despite the fall of its biggest single-earning product. AbbVie (NYSE: ABBV) investors might have a reason to start sweating. Imbruvica is underperform... | AbbVie (NYSE: ABBV) investors might have a reason to start sweating. That means that the pair will, in theory, be able to contest the markets that Humira is getting boxed out of by biosimilars, thereby maintaining AbbVie's base of revenue despite the fall of its biggest single-earning product. Imbruvica is underperform... | Imbruvica is underperforming The other number that could be problematic for AbbVie is $1.1 billion, which is the revenue generated by sales of Imbruvica, its therapy for lymphoma. AbbVie (NYSE: ABBV) investors might have a reason to start sweating. That means that the pair will, in theory, be able to contest the market... | Imbruvica is underperforming The other number that could be problematic for AbbVie is $1.1 billion, which is the revenue generated by sales of Imbruvica, its therapy for lymphoma. AbbVie (NYSE: ABBV) investors might have a reason to start sweating. That means that the pair will, in theory, be able to contest the market... |
23,373 | 2022-05-23 00:00:00 UTC | AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-files-nda-for-parkinsons-disease-candidate | null | null | AbbVie Inc. ABBV submitted a new drug application (“NDA”) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD) to the FDA.
The regulatory filing was based on data from a phase III head-to-head study, which showed that treatment with ABBV-951 ... | The regulatory filing was based on data from a phase III head-to-head study, which showed that treatment with ABBV-951 led to statistically significant improvement in "On" time without troublesome dyskinesia compared with oral immediate-release carbidopa/levodopa (CD/LD). The committee recommended approval of ABBV’s JA... | AbbVie Inc. ABBV submitted a new drug application (“NDA”) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD) to the FDA. The regulatory filing was based on data from a phase III head-to-head study, which showed that treatment with ABBV-951 ... | Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc. ABBV submitted a new drug application (“NDA”) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD) to the FDA. The regulatory filing was based on dat... | With many new indications coming in the next couple of years, AbbVie expects combined sales of Rinvoq and Skyrizi to be more than $15 billion by 2025. AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie Inc. ABBV submitted a new drug application (“NDA”) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of mot... |
23,374 | 2022-05-23 00:00:00 UTC | AbbVie:CHMP Recommends European Commission Approval Of Upadacitinib For Ulcerative Colitis Treatment | ABBV | https://www.nasdaq.com/articles/abbvie%3Achmp-recommends-european-commission-approval-of-upadacitinib-for-ulcerative-colitis | null | null | (RTTNews) - The European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion recommending the approval of upadacitinib (RINVOQ, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ul... | (RTTNews) - The European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion recommending the approval of upadacitinib (RINVOQ, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ul... | (RTTNews) - The European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion recommending the approval of upadacitinib (RINVOQ, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ul... | (RTTNews) - The European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion recommending the approval of upadacitinib (RINVOQ, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ul... | (RTTNews) - The European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion recommending the approval of upadacitinib (RINVOQ, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ul... |
23,375 | 2022-05-21 00:00:00 UTC | 7 Quality Dividend Stocks to Buy on the Dip | ABBV | https://www.nasdaq.com/articles/7-quality-dividend-stocks-to-buy-on-the-dip | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the current market evironment, investors could find solid ground with this dividend stocks to buy.
Merck (MRK): Robust results across its core portfolio, with its oncology portfolio expected to fire on all cylinders.
Chevron (CVX): Cash flow generating m... | AbbVie (ABBV): Reliance on Humira is decreasing, with several of its drugs becoming more popular. Ticker Company Price MRK Merck $ CVX Chevron $ CLX Clorox $ PG Procter & Gamble $ ABBV AbbVie $ XOM Exxon Mobil $ V Visa $ Dividend Stocks to Buy: Merck (MRK) Source: Atmosphere1 / Shutterstock.com Shares of healthcare gia... | Ticker Company Price MRK Merck $ CVX Chevron $ CLX Clorox $ PG Procter & Gamble $ ABBV AbbVie $ XOM Exxon Mobil $ V Visa $ Dividend Stocks to Buy: Merck (MRK) Source: Atmosphere1 / Shutterstock.com Shares of healthcare giant Merck (NYSE:MRK) have moved sluggishly as investors have rotated out of growth stocks. AbbVie (... | Ticker Company Price MRK Merck $ CVX Chevron $ CLX Clorox $ PG Procter & Gamble $ ABBV AbbVie $ XOM Exxon Mobil $ V Visa $ Dividend Stocks to Buy: Merck (MRK) Source: Atmosphere1 / Shutterstock.com Shares of healthcare giant Merck (NYSE:MRK) have moved sluggishly as investors have rotated out of growth stocks. AbbVie (... | Ticker Company Price MRK Merck $ CVX Chevron $ CLX Clorox $ PG Procter & Gamble $ ABBV AbbVie $ XOM Exxon Mobil $ V Visa $ Dividend Stocks to Buy: Merck (MRK) Source: Atmosphere1 / Shutterstock.com Shares of healthcare giant Merck (NYSE:MRK) have moved sluggishly as investors have rotated out of growth stocks. AbbVie (... |
23,376 | 2022-05-21 00:00:00 UTC | 7 Retirement Stocks to Buy for Any Market Conditions | ABBV | https://www.nasdaq.com/articles/7-retirement-stocks-to-buy-for-any-market-conditions | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although the market turmoil may have investors scrambling for cover, these retirement stocks can likely withstand the heat.
Brookfield Infrastructure (BIPC): One of the largest owners and operators of critical global infrastructure networks, Brookfield pres... | AbbVie (ABBV): As society gradually returns to normal, AbbVie’s Botox acquisition should make ABBV an enticing name among retirement stocks. 7 Dividend Stocks to Boost Your Retirement Savings Here are some intriguing names to consider for retirement stocks to buy: BIPC Brookfield Infrastructure Corporation $71.49 DUK D... | 7 Dividend Stocks to Boost Your Retirement Savings Here are some intriguing names to consider for retirement stocks to buy: BIPC Brookfield Infrastructure Corporation $71.49 DUK Duke Energy Corporation $109.42 AEP American Electric Power Company, Inc. $99.54 MRK Merck & Co., Inc. $93.48 ABBV AbbVie Inc. $152.46 XOM Exx... | 7 Dividend Stocks to Boost Your Retirement Savings Here are some intriguing names to consider for retirement stocks to buy: BIPC Brookfield Infrastructure Corporation $71.49 DUK Duke Energy Corporation $109.42 AEP American Electric Power Company, Inc. $99.54 MRK Merck & Co., Inc. $93.48 ABBV AbbVie Inc. $152.46 XOM Exx... | 7 Dividend Stocks to Boost Your Retirement Savings Here are some intriguing names to consider for retirement stocks to buy: BIPC Brookfield Infrastructure Corporation $71.49 DUK Duke Energy Corporation $109.42 AEP American Electric Power Company, Inc. $99.54 MRK Merck & Co., Inc. $93.48 ABBV AbbVie Inc. $152.46 XOM Exx... |
23,377 | 2022-05-20 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -4.3% over the past month versus the Zacks S&P 500 composite's -12.5% cha... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie... | Last Reported Results and Surprise History AbbVie reported revenues of $13.54 billion in the last reported quarter, representing a year-over-year change of +4.1%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has l... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs... | For the next fiscal year, the consensus earnings estimate of $11.81 indicates a change of -15.8% from what AbbVie is expected to report a year ago. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. Ab... |
23,378 | 2022-05-20 00:00:00 UTC | Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-fda-nod-to-pfe-covid-jab-for-age-5-11-llys-tirzepatide | null | null | This week, the FDA granted emergency authorization to booster shots of Pfizer PFE/BioNTech’s COVID-19 vaccine for use in children 5 to 11 years of age and also approved Lilly’s LLY novel diabetes treatment, Mounjaro (tirzepatide) injection. AbbVie ABBV and AstraZeneca AZN announced new licensing deals with small privat... | AbbVie ABBV and AstraZeneca AZN announced new licensing deals with small private biotechs. AbbVie Buys Option Rights to Novel Inflammation Candidate: AbbVie received an option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from precision medicines biot... | AbbVie Buys Option Rights to Novel Inflammation Candidate: AbbVie received an option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from precision medicines biotech, Cugene. AbbVie ABBV and AstraZeneca AZN announced new licensing deals with small priva... | AbbVie ABBV and AstraZeneca AZN announced new licensing deals with small private biotechs. AbbVie Buys Option Rights to Novel Inflammation Candidate: AbbVie received an option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from precision medicines biot... | AbbVie ABBV and AstraZeneca AZN announced new licensing deals with small private biotechs. AbbVie Buys Option Rights to Novel Inflammation Candidate: AbbVie received an option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from precision medicines biot... |
23,379 | 2022-05-20 00:00:00 UTC | AbbVie Submits NDA For ABBV-951 To FDA For Treatment Of Advanced Parkinson's Disease | ABBV | https://www.nasdaq.com/articles/abbvie-submits-nda-for-abbv-951-to-fda-for-treatment-of-advanced-parkinsons-disease | null | null | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).
The submission i... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). ABBV-951 is desi... | The NDA is based primarily on data from the M15-736 study, a Phase 3 randomized, double-blind, double-dummy, active-controlled study, which demonstrated statistically superior efficacy of ABBV-951 compared to oral immediate-release CD/LD in controlling motor fluctuations in advanced PD patients. (RTTNews) - Biopharmace... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). The NDA is based... | ABBV-951 is designed to provide a first-of-its-kind, 24-hour, continuous subcutaneous delivery of CD/LD. The NDA is based primarily on data from the M15-736 study, a Phase 3 randomized, double-blind, double-dummy, active-controlled study, which demonstrated statistically superior efficacy of ABBV-951 compared to oral i... |
23,380 | 2022-05-19 00:00:00 UTC | These 3 Stocks Have Doubled Over the Past 3 Years. Can They Do It Again? | ABBV | https://www.nasdaq.com/articles/these-3-stocks-have-doubled-over-the-past-3-years.-can-they-do-it-again | null | null | Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years. All three have the potential to double their shares again over the next three years because of their stability, consistent revenue growth, and attractive dividends... | I could easily see AbbVie doubling its share price within the next three years, particularly if it continues to watch its other immunology drugs other than Humira grow revenue. Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past... | Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years. AbbVie's deep pipeline keeps paying off AbbVie is trading for $155 a share. AbbVie isn't as reliant on blockbuster immunology drug Humira as some think. | Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years. AbbVie's deep pipeline keeps paying off AbbVie is trading for $155 a share. AbbVie isn't as reliant on blockbuster immunology drug Humira as some think. | Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years. AbbVie's deep pipeline keeps paying off AbbVie is trading for $155 a share. AbbVie isn't as reliant on blockbuster immunology drug Humira as some think. |
23,381 | 2022-05-18 00:00:00 UTC | 7 Best Value Stocks to Buy if You Need Some Market Stability in Your Life | ABBV | https://www.nasdaq.com/articles/7-best-value-stocks-to-buy-if-you-need-some-market-stability-in-your-life | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Weakness and long-term fear make investing in value stocks a strong idea right now.
Target (TGT): Earnings have been strong and Target is fundamentally strong.
D.R. Horton (DHI): Forces are in place for this home builder to continue to perform very well.
... | Horton $70.46 DE Deere $384.26 ABBV AbbVie $154.78 BRK-A BRK-B Berkshire Hathaway $314.60 PG Procter & Gamble $154.68 KO Coca-Cola $65.78 Target (TGT) Source: Sundry Photography / Shutterstock.com As I write this, on May 12, the Dow Jones continues its downward slide, falling by more than 1%. AbbVie (ABBV): Increased g... | Horton $70.46 DE Deere $384.26 ABBV AbbVie $154.78 BRK-A BRK-B Berkshire Hathaway $314.60 PG Procter & Gamble $154.68 KO Coca-Cola $65.78 Target (TGT) Source: Sundry Photography / Shutterstock.com As I write this, on May 12, the Dow Jones continues its downward slide, falling by more than 1%. AbbVie (ABBV): Increased g... | Horton $70.46 DE Deere $384.26 ABBV AbbVie $154.78 BRK-A BRK-B Berkshire Hathaway $314.60 PG Procter & Gamble $154.68 KO Coca-Cola $65.78 Target (TGT) Source: Sundry Photography / Shutterstock.com As I write this, on May 12, the Dow Jones continues its downward slide, falling by more than 1%. AbbVie (ABBV): Increased g... | Horton $70.46 DE Deere $384.26 ABBV AbbVie $154.78 BRK-A BRK-B Berkshire Hathaway $314.60 PG Procter & Gamble $154.68 KO Coca-Cola $65.78 Target (TGT) Source: Sundry Photography / Shutterstock.com As I write this, on May 12, the Dow Jones continues its downward slide, falling by more than 1%. AbbVie (ABBV): Increased g... |
23,382 | 2022-05-18 00:00:00 UTC | Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-outperforms-industry-this-year-so-far%3A-heres-why | null | null | Vertex Pharmaceuticals Incorporated VRTX stock has risen 19.2% this year so far against the industry’s decline of 25%.
Image Source: Zacks Investment Research
Vertex’s main area of focus is cystic fibrosis (CF). With its four CF medicines, Vertex is treating the majority of the 83,000 patients living with CF in the Un... | Recently, AbbVie ABBV completed an interim analysis of a phase II proof-of-concept study on its triple combination CF therapy. The failure of AbbVie’s CF therapy has removed a significant overhang on Vertex’s shares regarding competitive data. AbbVie Inc. (ABBV): Free Stock Analysis Report | Recently, AbbVie ABBV completed an interim analysis of a phase II proof-of-concept study on its triple combination CF therapy. The failure of AbbVie’s CF therapy has removed a significant overhang on Vertex’s shares regarding competitive data. AbbVie Inc. (ABBV): Free Stock Analysis Report | Recently, AbbVie ABBV completed an interim analysis of a phase II proof-of-concept study on its triple combination CF therapy. The failure of AbbVie’s CF therapy has removed a significant overhang on Vertex’s shares regarding competitive data. AbbVie Inc. (ABBV): Free Stock Analysis Report | Recently, AbbVie ABBV completed an interim analysis of a phase II proof-of-concept study on its triple combination CF therapy. The failure of AbbVie’s CF therapy has removed a significant overhang on Vertex’s shares regarding competitive data. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,383 | 2022-05-17 00:00:00 UTC | Is It Too Late to Buy AbbVie Stock? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-abbvie-stock-0 | null | null | Pharma giant AbbVie (NYSE: ABBV) has rewarded shareholders in the past decade with market-beating performance. That is especially noteworthy considering many pharma companies struggled through much of the 2010s as evidenced by the fact that the SPDR S&P Pharmaceutical ETF -- an industry benchmark -- substantially lagge... | AbbVie is a Dividend King, having raised its payouts for 50 consecutive years (including its time under the wing of medical-devices specialist Abbott Laboratories). Pharma giant AbbVie (NYSE: ABBV) has rewarded shareholders in the past decade with market-beating performance. AbbVie's strong showing was primarily a resu... | Pharma giant AbbVie (NYSE: ABBV) has rewarded shareholders in the past decade with market-beating performance. AbbVie's strong showing was primarily a result of its top-selling drug, Humira. How will AbbVie fare post-Humira? | Sales of AbbVie's aesthetics unit -- spearheaded by Botox Cosmetics -- grew by 20.5% year over year to $1.4 billion. First, as we have already seen, the company's lineup is strong enough to handle the inevitable sales drop that Humira will experience once it starts facing generic competition in the U.S. With the potent... | Pharma giant AbbVie (NYSE: ABBV) has rewarded shareholders in the past decade with market-beating performance. AbbVie's strong showing was primarily a result of its top-selling drug, Humira. How will AbbVie fare post-Humira? |
23,384 | 2022-05-17 00:00:00 UTC | AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-buys-option-rights-to-nextgen-inflammation-drug | null | null | AbbVie ABBV announced that it signed a deal with precision medicines biotech, Cugene, for CUG252, a potential best-in-class Treg-selective IL-2 mutein for the potential treatment of autoimmune and inflammatory diseases.
Per the deal, AbbVie will get an option to license worldwide rights for certain IL-2 muteins, includ... | Per the deal, AbbVie will get an option to license worldwide rights for certain IL-2 muteins, including a next-generation inflammatory candidate, CUG252, from Cugene. AbbVie ABBV announced that it signed a deal with precision medicines biotech, Cugene, for CUG252, a potential best-in-class Treg-selective IL-2 mutein fo... | AbbVie ABBV announced that it signed a deal with precision medicines biotech, Cugene, for CUG252, a potential best-in-class Treg-selective IL-2 mutein for the potential treatment of autoimmune and inflammatory diseases. Per the deal, AbbVie will get an option to license worldwide rights for certain IL-2 muteins, includ... | Zacks Rank and Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). AbbVie ABBV announced that it signed a deal with precision medicines biotech, Cugene, for CUG252, a potential best-in-class Treg-selective IL-2 mutein for the potential treatment of autoimmune and inflammatory diseases. Per the deal, AbbVie ... | AbbVie ABBV announced that it signed a deal with precision medicines biotech, Cugene, for CUG252, a potential best-in-class Treg-selective IL-2 mutein for the potential treatment of autoimmune and inflammatory diseases. Per the deal, AbbVie will get an option to license worldwide rights for certain IL-2 muteins, includ... |
23,385 | 2022-05-16 00:00:00 UTC | Japan pharma lobbies say pricing scheme leading to renewed 'drug lag' | ABBV | https://www.nasdaq.com/articles/japan-pharma-lobbies-say-pricing-scheme-leading-to-renewed-drug-lag | null | null | TOKYO, May 16 (Reuters) - Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to the government's drug-pricing system to avoid losing out on investment and new drugs.
While American and European drugmakers have complained for years about drug prices set by Japan's socialised... | Since 2015, there have been more than 50 changes to the system that determines how much companies can charge hospitals and patients for drugs, James Feliciano, the country manager for Abbevie Inc ABBV.N, told reporters. TOKYO, May 16 (Reuters) - Japan's three major pharmaceutical lobbies joined for the first time on Mo... | Since 2015, there have been more than 50 changes to the system that determines how much companies can charge hospitals and patients for drugs, James Feliciano, the country manager for Abbevie Inc ABBV.N, told reporters. While American and European drugmakers have complained for years about drug prices set by Japan's so... | Since 2015, there have been more than 50 changes to the system that determines how much companies can charge hospitals and patients for drugs, James Feliciano, the country manager for Abbevie Inc ABBV.N, told reporters. TOKYO, May 16 (Reuters) - Japan's three major pharmaceutical lobbies joined for the first time on Mo... | Since 2015, there have been more than 50 changes to the system that determines how much companies can charge hospitals and patients for drugs, James Feliciano, the country manager for Abbevie Inc ABBV.N, told reporters. While American and European drugmakers have complained for years about drug prices set by Japan's so... |
23,386 | 2022-05-16 00:00:00 UTC | 3 Dividend Stocks That Should Pay You for the Rest of Your Life | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-should-pay-you-for-the-rest-of-your-life-0 | null | null | If you've got some cash stored up, consider yourself a wise investor -- and fortunate. Now could be a great time to put that cash to use toward an investment in these three Dividend Kings that could provide robust returns for a lifetime.
Shares of AbbVie (NYSE: ABBV), Lowe's (NYSE: LOW), and Parker Hannifin (NYSE: PH) ... | AbbVie saw an average 21% year-over-year increase in sales across its aesthetics and neuroscience portfolios, led by strong demand for Botox Cosmetic, Juvederm, and the newly launched oral migraine drug, Ubrelvy. Shares of AbbVie (NYSE: ABBV), Lowe's (NYSE: LOW), and Parker Hannifin (NYSE: PH) more than tripled over th... | Shares of AbbVie (NYSE: ABBV), Lowe's (NYSE: LOW), and Parker Hannifin (NYSE: PH) more than tripled over the past 10 years as investor confidence remained strong. With revenue and earnings both showing growth, and a plan in place for its robust product portfolio, AbbVie should sustain its annual dividend increases and ... | With revenue and earnings both showing growth, and a plan in place for its robust product portfolio, AbbVie should sustain its annual dividend increases and provide passive income to investors for many years to come. Shares of AbbVie (NYSE: ABBV), Lowe's (NYSE: LOW), and Parker Hannifin (NYSE: PH) more than tripled ove... | Since then, AbbVie has increased its dividend by more than 250%. With revenue and earnings both showing growth, and a plan in place for its robust product portfolio, AbbVie should sustain its annual dividend increases and provide passive income to investors for many years to come. Shares of AbbVie (NYSE: ABBV), Lowe's ... |
23,387 | 2022-05-16 00:00:00 UTC | Buffett's Berkshire buys Citigroup and several other stocks, slashes Verizon | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-buys-citigroup-and-several-other-stocks-slashes-verizon | null | null | By Jonathan Stempel
May 16 (Reuters) - Berkshire Hathaway Inc BRKa.N on Monday said it added new investments in Citigroup Inc C.N and several other companies in the first quarter, as Warren Buffett's conglomerate took advantage of volatile stock markets to invest $51.1 billion that had largely been sitting in cash.
In ... | Stock sales totaled $9.7 billion, and also included drugmakers AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N. Berkshire also finally exited Wells Fargo & Co WFC.N, a 33-year-old investment that Buffett soured on after finding it too slow to address revelations that employees had mistreated customers, including by... | Stock sales totaled $9.7 billion, and also included drugmakers AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N. In a regulatory filing describing its U.S.-listed equity investments as of March 31, Berkshire reported new stakes in Ally Financial Inc ALLY.N, chemicals and specialty materials company Celanese Corp CE.... | Stock sales totaled $9.7 billion, and also included drugmakers AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N. By Jonathan Stempel May 16 (Reuters) - Berkshire Hathaway Inc BRKa.N on Monday said it added new investments in Citigroup Inc C.N and several other companies in the first quarter, as Warren Buffett's cong... | Stock sales totaled $9.7 billion, and also included drugmakers AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N. By Jonathan Stempel May 16 (Reuters) - Berkshire Hathaway Inc BRKa.N on Monday said it added new investments in Citigroup Inc C.N and several other companies in the first quarter, as Warren Buffett's cong... |
23,388 | 2022-05-16 00:00:00 UTC | 7 Retirement Stocks for Steady Long-Term Income Growth | ABBV | https://www.nasdaq.com/articles/7-retirement-stocks-for-steady-long-term-income-growth | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
As economic troubles loom, these retirement stocks should keep you in the black.
AbbVie (ABBV): strong portfolio for sustained dividend growth.
ASE Technology Holding (ASX): semiconductor demand from automotive tailwinds.
BCE (BCE): effective cost managemen... | MFC Manulife Financial $17.44 MO Altria Group $53.04 MRK Merck $90.41 PRU Prudential Financial $101.19 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) fell from its 52-week high of $175.91 after posting unimpressive first-quarter results and lowering its outlook. On its conference call, AbbVie’s ... | MFC Manulife Financial $17.44 MO Altria Group $53.04 MRK Merck $90.41 PRU Prudential Financial $101.19 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) fell from its 52-week high of $175.91 after posting unimpressive first-quarter results and lowering its outlook. AbbVie (ABBV): strong portfolio f... | MFC Manulife Financial $17.44 MO Altria Group $53.04 MRK Merck $90.41 PRU Prudential Financial $101.19 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) fell from its 52-week high of $175.91 after posting unimpressive first-quarter results and lowering its outlook. AbbVie (ABBV): strong portfolio f... | AbbVie (ABBV): strong portfolio for sustained dividend growth. ABBV AbbVie $153.50 ASX ASE Technology $6.62 MFC Manulife Financial $17.44 MO Altria Group $53.04 MRK Merck $90.41 PRU Prudential Financial $101.19 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) fell from its 52-week high of $175.91 ... |
23,389 | 2022-05-16 00:00:00 UTC | The 5 Best Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/the-5-best-dividend-stocks-to-buy-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors are shopping around for the best dividend stocks that could help weather an uncertain stock market.
Abbvie (ABBV): Anticipates its newer drugs, Skyrizi and Rinvoq, to generate a combined revenue of over $15 billion in 2025.
Exxon Mobil (XOM): Trip... | Abbvie (ABBV): Anticipates its newer drugs, Skyrizi and Rinvoq, to generate a combined revenue of over $15 billion in 2025. ABBV AbbVie $153.50 XOM Exxon $88.86 SLG SL Green $64.44 UPS United Parcel Service $178.04 VZ Verizon $48.18 Abbvie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV), the biopharma b... | ABBV AbbVie $153.50 XOM Exxon $88.86 SLG SL Green $64.44 UPS United Parcel Service $178.04 VZ Verizon $48.18 Abbvie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV), the biopharma behemoth, focuses on immunology and oncology. Abbvie (ABBV): Anticipates its newer drugs, Skyrizi and Rinvoq, to generate a c... | Abbvie (ABBV): Anticipates its newer drugs, Skyrizi and Rinvoq, to generate a combined revenue of over $15 billion in 2025. ABBV AbbVie $153.50 XOM Exxon $88.86 SLG SL Green $64.44 UPS United Parcel Service $178.04 VZ Verizon $48.18 Abbvie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV), the biopharma b... | ABBV AbbVie $153.50 XOM Exxon $88.86 SLG SL Green $64.44 UPS United Parcel Service $178.04 VZ Verizon $48.18 Abbvie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV), the biopharma behemoth, focuses on immunology and oncology. Beyond being one of the best dividend stocks to buy now ABBV is a dividend king... |
23,390 | 2022-05-14 00:00:00 UTC | 3 Supercharged Dividend Stocks to Buy in the Stock Market Sell-Off | ABBV | https://www.nasdaq.com/articles/3-supercharged-dividend-stocks-to-buy-in-the-stock-market-sell-off | null | null | Stock market crashes and corrections happen. Since the beginning of the year, the S&P 500 has been down over 17%. In fact, since the end of World War II, the benchmark index has tumbled more than 10% around 30 separate times.
A bear market of at least a 20% decline will also eventually happen again, maybe even this mon... | AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) still relies upon blockbuster anti-inflammatory drug Humira for the bulk of its revenue -- $4.7 billion in the first quarter, or 35% of the total $13.5 billion generated -- but the rise of biosimilars will eventually take its toll. And AbbVie has other big drugs that are ... | AbbVie is a solid growth business and pays a dividend yielding 3.7% annually. AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) still relies upon blockbuster anti-inflammatory drug Humira for the bulk of its revenue -- $4.7 billion in the first quarter, or 35% of the total $13.5 billion generated -- but the rise of biosi... | AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) still relies upon blockbuster anti-inflammatory drug Humira for the bulk of its revenue -- $4.7 billion in the first quarter, or 35% of the total $13.5 billion generated -- but the rise of biosimilars will eventually take its toll. And AbbVie has other big drugs that are ... | AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) still relies upon blockbuster anti-inflammatory drug Humira for the bulk of its revenue -- $4.7 billion in the first quarter, or 35% of the total $13.5 billion generated -- but the rise of biosimilars will eventually take its toll. AbbVie's neuroscience portfolio also con... |
23,391 | 2022-05-13 00:00:00 UTC | Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-pfes-biohaven-buyout-offer-bayrys-q1-earnings-update | null | null | This week, Pfizer PFE offered to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer BAYRY announced first-quarter 2022 earnings. Roche RHHBY announced disappointing data from a phase III PD-L1-high metastatic non-small cell lung cancer (NSCLC)study. The FDA granted full approval to Eli Lilly LLY ... | AbbVie’s ABBV Rinvoq achieved clinical remission and endoscopic response at one year in a phase III maintenance study in patients with Crohn's disease. AbbVie’s Rinvoq Meets Goal in Crohn’s Disease Study: AbbVie’s U-ENDURE, a phase III maintenance study evaluating Rinvoq (upadacitinib) in adult patients with moderate t... | AbbVie’s ABBV Rinvoq achieved clinical remission and endoscopic response at one year in a phase III maintenance study in patients with Crohn's disease. AbbVie’s Rinvoq Meets Goal in Crohn’s Disease Study: AbbVie’s U-ENDURE, a phase III maintenance study evaluating Rinvoq (upadacitinib) in adult patients with moderate t... | AbbVie’s Rinvoq Meets Goal in Crohn’s Disease Study: AbbVie’s U-ENDURE, a phase III maintenance study evaluating Rinvoq (upadacitinib) in adult patients with moderate to severe Crohn's disease met the primary endpoint. AbbVie’s ABBV Rinvoq achieved clinical remission and endoscopic response at one year in a phase III m... | AbbVie’s ABBV Rinvoq achieved clinical remission and endoscopic response at one year in a phase III maintenance study in patients with Crohn's disease. AbbVie’s Rinvoq Meets Goal in Crohn’s Disease Study: AbbVie’s U-ENDURE, a phase III maintenance study evaluating Rinvoq (upadacitinib) in adult patients with moderate t... |
23,392 | 2022-05-13 00:00:00 UTC | 1 Company Disrupting Plastic Surgery, Not Patients | ABBV | https://www.nasdaq.com/articles/1-company-disrupting-plastic-surgery-not-patients | null | null | In a world where the word "selfie" translates into every language, more and more people want to look their best -- preferably without surgery. InMode (NASDAQ: INMD) is riding the wave of safer and faster results for patients, with industry-leading minimal and non-invasive RF technology that displaces painful liposuctio... | Thus far, the company's only real rival in non-invasive cosmetic treatments is AbbVie's (NYSE: ABBV) Allergan, which sells CoolSculping systems that freeze fat cells, later expelled by the body. InMode (NASDAQ: INMD) is riding the wave of safer and faster results for patients, with industry-leading minimal and non-inva... | Thus far, the company's only real rival in non-invasive cosmetic treatments is AbbVie's (NYSE: ABBV) Allergan, which sells CoolSculping systems that freeze fat cells, later expelled by the body. Cutting through the fat InMode uses bipolar radio frequency technology for body sculpting, fat reduction, wrinkle reduction, ... | Thus far, the company's only real rival in non-invasive cosmetic treatments is AbbVie's (NYSE: ABBV) Allergan, which sells CoolSculping systems that freeze fat cells, later expelled by the body. InMode's systems deliver either pulse treatment, which doesn't burn skin, or continuous treatment, which monitors skin temper... | Thus far, the company's only real rival in non-invasive cosmetic treatments is AbbVie's (NYSE: ABBV) Allergan, which sells CoolSculping systems that freeze fat cells, later expelled by the body. According to InMode's 2021 annual report , its technology is the first and only RF-based, non-invasive body contouring techno... |
23,393 | 2022-05-13 00:00:00 UTC | 3 Dividend Stocks You Can Buy and Hold for Decades | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-you-can-buy-and-hold-for-decades-0 | null | null | You've probably heard the phrase "Think long term" quite a bit if you've been an investor for a while. But what time frame qualifies as a long-term horizon? There's no magic number, but 10 years seems to be a good minimum threshold.
However, there are some stocks with such strong underlying businesses that even 10 year... | AbbVie AbbVie (NYSE: ABBV) offers one of the most impressive dividend pedigrees around. Since spinning off from Abbott in 2013, AbbVie has increased its dividend by more than 250%. AbbVie has met or exceeded its adjusted earnings per share guidance in every quarter since it became an independent entity. | See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie AbbVie (NYSE: ABBV) offers one of the most impressive dividend pedigrees around. Since spinning off from Abbott in 2013, AbbVie has in... | Brookfield Renewable Brookfield Renewable (NYSE: BEP) (NYSE: BEPC) hasn't been around long enough to compile a track record like AbbVie's. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. Ab... | AbbVie AbbVie (NYSE: ABBV) offers one of the most impressive dividend pedigrees around. Since spinning off from Abbott in 2013, AbbVie has increased its dividend by more than 250%. AbbVie has met or exceeded its adjusted earnings per share guidance in every quarter since it became an independent entity. |
23,394 | 2022-05-12 00:00:00 UTC | July 1st Options Now Available For AbbVie | ABBV | https://www.nasdaq.com/articles/july-1st-options-now-available-for-abbvie | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the July 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new July 1st contracts and identified one put and one call contract of particular interest.
The put contract at ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Considering the fact that the $155.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $150.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $155.00 strike price has a current bid of $4.25. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new July 1st contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Considerin... |
23,395 | 2022-05-12 00:00:00 UTC | Pharma Stocks: The Perfect Cure in an Unhealthy Environment? | ABBV | https://www.nasdaq.com/articles/pharma-stocks%3A-the-perfect-cure-in-an-unhealthy-environment | null | null | The COVID-19 pandemic resulted in several pharmaceutical companies profiting handsomely with robust sales from COVID-19 vaccines. This has also resulted in pharma companies faring relatively better in the stock market vis-à-vis other sectors, even amid the current market volatility. While pharma stocks like Pfizer have... | AbbVie updated its adjusted diluted EPS guidance for FY22 to range between $13.92 and $14.12 from $14 to $14.20 per share earlier to account for the “unfavorable impact of $0.08 per share related to acquired IPR&D [in process research and development] and milestones expense incurred during the first quarter 2022.” ABBV... | While pharma stocks like Pfizer have seen their stock price drop around 13% this year, other stocks in this sector including AbbVie, Bristol Myers-Squibb, and Merck (MRK) have seen their stock prices rise by 12.2%, 23.1%, and 16%, respectively. Using the TipRanks stock comparison tool, we will compare three such value ... | While pharma stocks like Pfizer have seen their stock price drop around 13% this year, other stocks in this sector including AbbVie, Bristol Myers-Squibb, and Merck (MRK) have seen their stock prices rise by 12.2%, 23.1%, and 16%, respectively. However, Mizuho Securities analyst Vamil Divan is bullish “on the AbbVie st... | However, Mizuho Securities analyst Vamil Divan is bullish “on the AbbVie story given the more diversified growth we believe they are poised to deliver, although we acknowledge uncertainty around the impact of the upcoming Humira US loss of exclusivity will likely keep shares trading at a discount to its peers.” The ana... |
23,396 | 2022-05-12 00:00:00 UTC | Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID | ABBV | https://www.nasdaq.com/articles/lillys-lly-olumiant-gets-full-approval-from-fda-for-covid | null | null | Eli Lilly and Company LLY and partner Incyte INCY announced that the FDA has granted full approval to their JAK inhibitor, Olumiant (baricitinib) for treating COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Lilly and Incyte’s Olumiant has been available in the United States for trea... | Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... | AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... | Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... | Some other popular JAK inhibitor medicines available are AbbVie’s ABBV Rinvoq (upadacitinib) and Pfizer’s PFE Xeljanz. AbbVie’s Rinvoq is approved for RA, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. AbbVie expects Rinvoq to be its key top-line driver when generics of its blockbuster immunology me... |
23,397 | 2022-05-11 00:00:00 UTC | AbbVie Announces Positive Topline Results From U-ENDURE Phase 3 Study Evaluating Upadacitinib | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-topline-results-from-u-endure-phase-3-study-evaluating | null | null | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy.... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy.... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy.... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy.... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy.... |
23,398 | 2022-05-11 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, Qualcomm, Linde, CVS Health Corp, and Booking Holdings | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-qualcomm-linde-cvs-health-corp-and-booking | null | null | For Immediate Release
Chicago, IL – May 11, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Qualcomm Inc... | Today's Featured Reports Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+37.0% vs. +20.5%) on the back of the company's successful label expansion of its cancer drugs, Imbruvica and Venclexta. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Qualcomm I... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Qualcomm Inc. QCOM, Linde plc LIN, CVS Health Corp. CVS, and Booking Holdings Inc. BKNG. Here are highlights from Tuesday’s Analyst Blog: Q1 Earnings Scorecard & Analyst Reports for AbbVie, Qualcomm & Linde The Zacks Research Daily presents the best resear... | Here are highlights from Tuesday’s Analyst Blog: Q1 Earnings Scorecard & Analyst Reports for AbbVie, Qualcomm & Linde The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features update on the 2022 Q1 earnings season and new research reports on 16 major stocks, includi... | Here are highlights from Tuesday’s Analyst Blog: Q1 Earnings Scorecard & Analyst Reports for AbbVie, Qualcomm & Linde The Zacks Research Daily presents the best research output of our analyst team. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Qualcomm Inc. QCOM, Linde plc LIN, CVS Health Corp. CVS, a... |
23,399 | 2022-05-11 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-0 | null | null | If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $2.43 bil... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the Fir... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the Fir... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report Alternatives First Trust Morningstar Dividend Leaders ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected ... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the Fir... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.